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ABSTRACT
Opioids currently represent the best treatment option for severe and
chronic pain conditions. Opioids while effective at controlling pain states also
come with a number of side effects such as respiratory depression, urinary
retention, dependence, tolerance, and opioid-induced hypernociception (OIH).
OIH is a phenomenon in which opioids induce pain and this pain is often
experienced at a site separate from the site of injury. Much research has been
conducted investigating the mechanism of OIH, but the mechanism remains
unsolved. One potential mechanism that has yet to be adequately explored is
chemokines. Chemokines role in OIH is warranted given recent studies
demonstrating the interaction between opioids and chemokines. Chemokines
were originally thought to solely function in the immune system, but have recently
been found to play a major role in the nervous system, as well as being
implicated in a number of different pain models. Therefore, the purpose of these
studies was to investigate a possible interaction between opioids and
chemokines in the peripheral nervous system and the role this interaction plays
in the development and maintenance of OIH. To do this, I tested for changes in
expression of SDF1 and CXCR4 signaling in the dorsal root ganglion following
repeated morphine administration. Secondly, I investigated if opioid or nonopioid signaling was involved in the development of OIH and which of these

XV

receptor signaling cascades was responsible for changes in SDF1/CXCR4
signaling in the dorsal root ganglion. These studies employed the use of a
number of different methods including animal behavior, in situ hybridization,
immunocytochemistry, and calcium imaging.
It was found that SDF1/CXCR4 signaling was indeed increased in OIH
and that these changes in SDF1/CXCR4 signaling occur following activation of
the mu opioid receptor. Additionally, OIH appears to be induced by both opioid
and non-opioid receptor signaling. These results suggest that opioids are
inducing a neuroinflammatory process that can be detrimental at anatomical sites
separate from an injury. Therefore, to improve the analgesic effectiveness of
opioids these off target effects must be considered and new treatments that can
bypass these effects should be explored.
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CHAPTER ONE
INTRODUCTION
Pain
The ability to experience pain has a beneficial role in humans and
animals. For example, the ability to withdraw your hand following touching a hot
object protects against tissue damage. Sherrington more than a century ago
defined this type of stimulus as noxious, a stimulus with potential to damage
tissue (Sherrington, 1906). Therefore, it is beneficial to be able to distinguish
between noxious and non-noxious stimuli. Acute pain perception is essential for
avoiding potential tissue damaging events which may hinder the healing process.
In contrast, pain that persists beyond the wound healing period serves no
beneficial role. In fact, this type of chronic pain contributes to deterioration in the
quality of life. Chronic pain states are characterized using the following terms:
hyperalgesia (increased sensitivity to painful stimuli), allodynia (non-noxious
stimuli perceived as painful) and increased spontaneous pain. It is important to
note that pain involves the perception of pain and is a subjective experience.
Therefore, animal models often employ the term nociception which involves
observations of neural, physiological, and behavioral changes.

1

2

Nociceptive Pathway
The nociceptive signal originates from stimuli activating nociceptors on
primary afferent sensory neurons (Fig.1). Primary afferent sensory neurons
transduce stimuli to an electrical signal that is then transmitted up the sensory
neuron axon to the dorsal horn of the spinal cord, the site of the first synapse of
the signal. Interneurons within the lamina I-II of the dorsal horn receive input
from primary afferent neurons and are responsible for initiating the withdrawal
reflex permitting fast reaction to potentially damaging stimuli. Primary afferent
sensory neurons also synapse with second order neurons of lamina I-II within the
dorsal horn of the spinal cord which transmit the signal to higher centers in the
central nervous system, thalamus and cortex; transmission of this signal is
referred as the ascending pathway. These supraspinal centers are responsible
for the conscious and emotional experience of pain, are the site of conscious
perception of pain in humans. Descending pathways originate in the cortex and
project to the periaqueductal grey (PAG). Inhibitory neurons in PAG send axons
to spinal cord dorsal horn and modulate incoming noxious signals from the
periphery. The descending pathway is often referred to as the modulatory
pathway because it synapses with dorsal horn and primary sensory neurons and
can regulate the level of excitation of the nociceptive signal. Therefore, the
nociceptive pathway has a built-in feedback system by which it can regulate the
nociceptive experience.

3

Figure 1. Nociceptive Pathway.
Brain clipart
(http://www.artvex.com/content/Clip_Art/Anatomy/Brains/0015438.gif),
Hand clipart (http://cliparts101.com/free_clipart/24783/hand.aspx)

Components of Dorsal Root Ganglia
Sensory Neurons
Primary afferent sensory neurons are psuedounipolar neurons. Sensory
neurons have a single axon composed of two branches that extend from the cell
body located in the dorsal root ganglion (DRG). One branch of the axon extends
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to peripheral tissues such as skin, muscle, and viscera. This branch of the
sensory neuron is responsible for sensing changes in temperature, touch,
proprioception, and pain in the environment. The other branch of the sensory
neuron extends into the dorsal horn of the spinal cord where it synapses and
relays information from the periphery for further processing within the spinal and
supraspinal level.
Sensory neurons within the DRG vary in size, degree of myelination, and
conduction velocity. Large diameter, Aα, and medium diameter, Aβ, sensory
neurons are both fast conducting, myelinated axons that are in charge of relaying
information about touch and proprioception. A subset of sensory neurons,
nociceptive neurons, transmit sensory information about potentially damaging
stimuli and thus are responsible for transmitting pain signals. Nociceptive
sensory neurons are polymodal responding to mechanical, thermal, and chemical
stimuli and are further divided into two types, Aδ and C fibers. Aδ are fast
conducting, myelinated fibers and are often referred to as high-threshold
mechanoreceptors (Burgess and Perl, 1967). Aδ fibers are responsible for
transmitting the initial stimuli of nociception. C fibers are slow conducting,
unmyelinated fibers and transmits a less robust signal.
Sensory neurons have very unique and interesting characteristics. DRG
neurons express receptors for neurotransmitter such as, glutamate, serotonin,
ATP, bradykinin, Substance P, and GABA (Sato et al., 1993; Huettner, 1990;
Lovinger and Weight, 1988; Todorovic and Anderson, 1990; Bean et al., 1990;
Bouvier et al., 1991; Thayer et al., 1988; Spigelman and Puil, 1991; Aibara and
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Akaike, 1991; Robertson, 1989). Cell somas of the DRG are devoid of any
dendrites and synapses, but are capable of releasing neurotransmitters and
inflammatory mediators such as CGRP, Substance P, and glutamate in a
calcium- dependent manner (Hingtgen and Vasko, 1994; Mason et al., 1984;
Vedder and Otten, 1991; Holz et al., 1988; Jeftinija and Jeftinija, 1990; Huang
and Neher, 1996). DRG neurons are capable of sensing activity in neighboring
neurons through transient depolarization (Liu et al., 1999; Utzschneider et al.,
1992; Amir and Devor, 1996), changing their excitable state following nerve injury
(Wall and Devor, 1983) and increasing the expression of sodium channels
following inflammatory pain models (Tanaka et al., 1998; Gould et al., 1998). All
of these changes would serve to change the excitability state of sensory neurons
and thus change the state of the nociceptive pathway as a whole.
Satellite Glial Cells
The other important component of the DRG are satellite glial cells (SGCs)
which surround each sensory neuron. Glial cell involvement in the nervous
system has only recently begun to be explored. Glial cells were once thought to
solely function as their name describes as the “glue” of the nervous system
holding neurons in place. However, research conducted in recent decades has
begun to demonstrate the importance of these cells in the physiology of the
nervous system. Glial cells regulate the environment of the neurons they
surround (Hansson and Ronnback, 2003; Reichenbach, 1991), as well as being
important in the developing nervous system (Slezak and Pfrieger, 2003;
Goldman, 2003). There is very little known about SGCs but they do express
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receptors, transporters, ion channels, and ligands demonstrating their ability to
signal and regulate the environment in the DRG (reviewed in (Hanani, 2005)).
SCCs are unique in that they form a protective envelope/sheath around the
sensory neurons of the DRG. Each sensory neuron is surrounded by several
SGCs possibly serving to form a functional unit between each sensory neuron
and its surrounding SGCs (Pannese, 1981; Hanani, 2005). Although the SGCs
form an envelope around each sensory neuron, ions, neurotransmitters, and
macromolecules are able to penetrate through the sheath allowing for crosscommunication among sensory neurons in the DRG (Shinder and Devor, 1994).
The SGC envelope can also serve to protect sensory neurons from toxic
substances such as mercury and lead (Kumamoto et al., 1986; Schlaepfer,
1969). Therefore, it appears that the SGCs serve as the barrier for the sensory
neuron’s cell bodies within the DRG. Taken together these characteristics
demonstrate the critical role SGCs have to regulate the environment of neurons.
Satellite glial cells are capable of increases in intracellular calcium levels
in response to stimuli (England et al., 2001). Indeed, it appears that neuronal
response to inflammatory mediators such as, bradykinin, is dependent on contact
with SGCs (Heblich, 2001). Additionally, SGCs properties such as increased
glial cell coupling and more depolarized resting membrane potential can be
altered following chronic compression of the DRG (Zhang et al., 2009). Other
interactions have been demonstrated between sensory neurons and SGCs
through mechanisms involving the paracrine interaction of cytokine interleukin-1β
(IL-1β) within the DRG. IL-1β expression is increased in SGCs following
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complete Freund’s adjuvant (CFA) injection (Takeda et al., 2007). CFA
treatment also induces increased firing frequency of sensory neurons (Takeda et
al., 2007). Interleukin-1 receptor antagonist treatment inhibits spontaneous and
mechanical stimulation-induced increased neuronal firing frequency in CFA
treated animals (Takeda et al., 2008), suggesting IL-1β is released from SGCs
and acting on sensory neurons to induce the increased firing frequency. To this
end, it appears that the satellite glial cells may play a crucial role in the signaling
and modulating interactions that occur within the DRG.
Clinical Treatments for Acute and Chronic Pain
There are a number of treatment options for acute pain states, such as
local anesthetics which temporarily prevent neuronal activity. Acute inflammatory
pain states resulting from trauma or surgical procedures are often controlled with
the use of non-steroidal anti-inflammatory drugs (NSAIDS). Where there is a
lack of effective treatment options are in chronic clinical pain states. While a
large percentage of the population suffer from chronic pain 40-50 percent of
these individuals do not have adequate relief of their pain (Glajchen, 2001). The
class of therapeutics prescribed varies for depending on severity level and time
course of the pain state. Neuropathic pain states that result from injury to the
nervous system, have limited treatment with only anti-convulsants and tri-cyclic
anti-depressants being prescribed and have limited effectiveness. These drugs
are chosen for their potential to decrease cell excitability. Chronic pain from
inflammatory conditions is largely controlled by non-steroidal anti-inflammatory
drugs (NSAIDS). In the case of severe pain states opioid analgesics are often
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prescribed in an attempt to control pain because of their substantial analgesic
ability. Opioids which target opioid receptors are often effective in controlling
pain; however, they come with a number of side effects, such as respiratory
depression, urinary retention, dependence, tolerance and finally opioid-induced
hypernociception, which will be explained in more detail in later sections.
G Protein Coupled Receptors
G-protein coupled receptors (GPCRs) are a large family of receptors that
represent the target receptor for the majority of physiologically relevant ligands.
GPCRs are seven transmembrane receptors that are coupled to heterotrimeric G
proteins. Ligand binding to the receptor initiates a conformational change
allowing for the activation of the G protein. The heterotrimeric G protein is
composed of α, β, and γ subunits. G proteins are classified by their α subunit
and each α subunit initiates a different cascade of events. Gs which activates
adenylyl cylclase, Gi which inhibits adenylyl cylcase, and Go and Gq which
activate phospholipase C which then activates IP3 and diacylglycerol production.
GPCR signaling can be regulated through the desensitization process.
Following ligand binding to the GPCR, the GPCR is phosphorylated by G-proteinlinked receptor kinases (GRKs). GRK phosphorylation of the receptor allows for
arrestin binding to the receptor. Arrestin binding to the receptor sterically hinders
the G-protein from binding to the receptor, thereby uncoupling the G-protein from
the receptor and preventing further receptor activation. Arrestin binding to the
receptor can also serve to initiate receptor internalization, further preventing
ligand and receptor signaling events.
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Opioid Receptors
Opioid receptors are a family of seven transmembrane GPCRs that
consist of three types, µ (MOR), δ (DOR), and κ (Kappa). Opioid receptors are
thought to be Gi coupled receptors. Some studies have suggested that opioid
receptors are also Gs coupled under both naïve and morphine treated conditions
(Chakrabarti and Gintzler, 2007; Chakrabarti et al., 2005; Chakrabarti et al.,
1998). All three opioid receptors were identified and cloned in the early 1990s
(Evans et al., 1992; Chen et al., 1993; Meng et al., 1993). MOR, DOR, and KOR
have homologous sequences, with the highest conserved sequences in the
transmembrane and intracellular regions (63-76%). However, the extracellular
regions, typically responsible for ligand binding are less conserved (34-30%)
(Minami and Satoh, 1995).
Opioid receptors are expressed throughout the nervous system both
centrally and peripherally. In particular opioid receptor expression correlates
strongly with the regions important in the nociceptive pathway. Opioid receptors
are located in lamina I-III of the spinal cord and at the supraspinal level with the
greatest expression in the striatum, amygdala, thalamus, and PAG of the central
nervous system (Kuhar et al., 1973; Pert et al., 1976; Lamotte et al., 1976; Atweh
and Kuhar, 1977; Fields et al., 1980; Ninkovic et al., 1982). Peripheral
distribution of the opioid receptors extends to cutaneous skin (Stein et al., 1990;
Pare et al., 2001) and all opioid receptors are expressed on small, medium, and
large diameter DRG neurons (Fields et al., 1980; Mansour et al., 1994; Minami et
al., 1995; Buzas and Cox, 1997; Chen et al., 1997; Coggeshall et al., 1997;
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Zhang et al., 1998; Wang and Wessendorf, 2001; Silbert et al., 2003; Rau et al.,
2005; Gendron et al., 2006).
Opioid Agonists and Antagonists
Each opioid receptor has both endogenous and exogenous ligands for
which they have varying binding affinities, outlined in the table below.
Exogenous natural and synthetic opioids are often employed for pain treatment.
The analgesic mechanism of action of opioid agonists has long been believed to
be through MOR. This can be witnessed in the prototypical opioid analgesic,
morphine, which has its greatest affinity for the MOR (14 nM) followed by lesser
affinity for KOR (538 nM) and DOR (>1000 nM) (Raynor et al., 1994) (Table 1).
Selective opioid agonists and antagonists exist for each of the opioid receptors
and are often employed as pharmacological tools for identifying the role of each
receptor in signaling events. For example, DAMGO, a selective exogenous MOR
agonist, has a 1000 fold greater affinity for the MOR over DOR and KOR (Schiller
et al., 1989; Schiller et al., 1990; Raynor et al., 1994) (Table 1). Non-selective
opioid antagonists naloxone and naltrexone have similar affinities for the opioid
receptors (Table 1), but differ by naltrexone having a longer half life than
naloxone (Verebey et al., 1976).
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Receptor Type
µ (MOR)

Agonists
DAMGO
Morphine

Κ (KOR)

U-50,488
Morphine

δ (DOR)

DPDPE
Deltorphin
Morphine

Antagonists
CTAP
Naloxone
Naltrexone
Nor-BNI
Naloxone
Naltrexone
Naltrindole
Naloxone
Naltrexone

Table 1. Opioid agonists and antagonists for each of the opioid receptors.

Peripheral versus Central Opioid Analgesic Actions
Opioid receptors are expressed throughout the central and peripheral
nervous system as outlined previously; therefore the analgesic actions of opioid
agonists could be acting through both. Classically, opioid agonists have been
thought to carry out their analgesic ability through actions in the spinal and
supraspinal level, such as the PAG. However, the ability of opioids to carry out
their analgesic ability through acting on peripheral sites is possible because
opioid receptors are located on sensory neurons (Fields et al., 1980; Mansour et
al., 1994; Minami et al., 1995; Buzas and Cox, 1997; Chen et al., 1997;
Coggeshall et al., 1997;Zhang et al., 1998; Wang and Wessendorf, 2001; Silbert
et al., 2003; Rau et al., 2005; Gendron et al., 2006) and co-localize with known
nociceptive substances, CGRP and Substance P (Dado et al., 1993; Wenk and
Honda, 1999; Minami et al., 1995). Additional evidence for opioids peripheral
analgesic ability is provided by studies demonstrating activation of mu opioid
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receptors on sensory neurons induces: (1) a decrease in spontaneous activity
(Russell et al., 1987), (2) decrease in calcium currents (Werz and Macdonald,
1982; Borgland et al., 2001), (3) decrease in non-selective cation currents
(Ingram and Williams, 1994), and (4) inhibits activation through prostaglandin
(Gold et al., 1996), Transient Receptor Potential Vanillioid 1 (TRPV1) (EndresBecker et al., 2007), and purinergic receptors (Chizhmakov et al., 2005). Several
studies support peripheral action of opioid analgesics through the use of
peripherally restricted opioid agonists and antagonists (Stein et al., 1991; Barber
et al., 1994; Aley et al., 1995; Zhou et al., 1998; Likar et al., 1999; Machelska et
al., 1999; Koppert et al., 1999; Pertovaara and Wei, 2001; Dionne et al., 2001;
Reichert et al., 2001; Shannon and Lutz, 2002; Junger et al., 2002; Furst et al.,
2005; Labuz et al., 2007; Mousa et al., 2007). In fact, it has been demonstrated
that 50-80% of the analgesic ability of systemically administered opioids is
carried out through their actions on peripheral targets (Reichert et al., 2001;
Shannon and Lutz, 2002; Furst et al., 2005; Labuz et al., 2007).
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Figure 2. Morphine Structure. Free hydroxyl groups at position 3
and 6 are the sites of glucuronide conjugation.

Morphine Metabolism
Morphine undergoes first pass metabolism and is mainly metabolized in
the liver by the process of glucuronidation. Glucuronidation is a conjugation
process carried out by the hepatic enzyme UDP-glucuronyl transferase,
UGT2B7. Glucuronide conjugation can occur at both the 3 and 6 position free
hydroxyl sites on the morphine structure (Fig. 2) resulting in the formation of the
two major metabolites of morphine, morphine-3-glucuronide (M3G) and
morphine-6-glucuronide (M6G) (reviewed in (Coller et al., 2009)). M6G shares
similar affinities at MOR, DOR, and KOR as its parent compound, morphine
(Pasternak et al., 1987) and 9-10% of morphine is converted to M6G (Osborne et
al., 1990; Hasselstrom and Sawe, 1993). Because M6G has similar affinity for
the MOR its analgesic ability is retained (Pasternak et al., 1987; Penson et al.,
2000).

M3G is the major metabolite of morphine with 44-55% of morphine

being converted to M3G (Osborne et al., 1990; Hasselstrom and Sawe, 1993).
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Although M3G is a major metabolite of morphine it has very little affinity for the
MOR, DOR, and KOR opioid receptors (Pasternak et al., 1987) with a greater
than 100 fold less affinity for the MOR compared to morphine (Skarke et al.,
2005). M3G’s loss of affinity for the opioid receptors is attributed to the lack of a
free 3-hydroxyl group that is needed for strong affinity to opioid receptor binding
(Pert and Snyder, 1973). Thus, because M3G has limited affinity for the opioid
receptors it does not possess analgesic abilities (Pasternak et al., 1987; Ekblom
et al., 1993). In fact, M3G has been proposed to be responsible for the negative
side effects following morphine administration. Increased plasma and cerebral
spinal fluid levels of M3G correlate with decreases in analgesic activity of
morphine (Baker and Ratka, 2002; Barjavel et al., 1995). M3G has also been
shown to antagonize the analgesic effects of morphine when co-administered
(Smith et al., 1990) and can be neuroexcitatory and lead to nociceptive behavior
(Bartlett et al., 1994; Labella et al., 1979; Yaksh et al., 1986; Woolf, 1981; Lewis
et al., 2010). Therefore, it is believed that the morphine metabolite, M3G, could
be responsible for one of the negative side effects of morphine such as, opioidinduced hypernociception.
Opioid-Induced Hypernociception
Opioids, such as morphine, currently represent the best option for the
management of moderate to severe trauma-induced, perioperative and cancer
pain. Opioid compounds are also increasingly being used for chronic, noncancer chronic pathological pain. However, prolonged administration of opiates
is associated with significant problems including the development of
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antinociceptive tolerance, wherein higher doses of the drug are required over
time to elicit the same amount of analgesia. These higher doses are also
thought to increase pain sensitivity, a concept known as opioid-induced
hypernociception (OIH). This increased pain is usually experienced at a location
separate from the original site of injury (Ossipov et al., 2004).
OIH has been observed both clinically (Angst et al., 2003; Arner et al.,
1988; Singla et al., 2007) and experimentally (Laulin et al., 1999; Woolf, 1981).
Many explanations for this phenomenon have been suggested. For example,
OIH was once believed to occur as a result of ‘‘mini withdrawals’’, however OIH
still occurs when opiates are constantly infused (Vanderah et al., 2000; Vanderah
et al., 2001). Some investigators will even go so far as to suggest that OIH is
actually a form of antinociceptive tolerance, in which patients require a greater
opiate dose in order to receive the same analgesic effect (Guignard et al., 2000;
Luginbuhl et al., 2003). Yet another explanation is that the hyperalgesic
response to morphine is caused by a compensatory response to the inhibition
produced by activation of the mu opioid receptor (MOR), causing a hyperactivity
of the system (Gutstein, 1996). In fact, higher doses are suggested to precipitate
this effect largely because the hyperactive state becomes more dominant
(Colpaert, 2002).
Release of the neurotransmitter, glutamate, has also been implicated as an
entity involved in OIH. To this end, glutamate antagonism in the dorsal horn of
the spinal cord has been somewhat effective in temporarily reversing OIH
(Celerier et al., 2000; Laulin et al., 1998). The involvement of glutamate
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receptors is not surprising because the long lasting effects that are witnessed in
OIH would require neural plasticity, changes that likely require glutamate
receptors. However, the ability of glutamate blockade to effectively treat OIH is
questioned. This is because the neural plastic changes that are occurring are
present in two parts; i) the sensitivity of the glutamate receptor, and ii) the
perceived decreased responsiveness of the MOR. Blockade of the glutamate
receptor would transiently reverse the nociceptive behavior, however it does not
address the changes that have occurred in the MOR bearing cells (Mao et al.,
1995). Despite a considerable amount of work on the topic little is known about
the underlying mechanism.
Much of the current studies on OIH have focused on the CNS, but the
mechanism of OIH largely remains unsolved. Given the peripheral actions of
opioids outlined previously, peripheral opioid mechanisms role in the induction of
OIH seems likely, but have largely been unexplored. Another potential
mechanism that has yet to be explored in OIH is the role of chemokines which in
recent years has been connected to many pain models.
Interaction between Opioids and Chemokines
Chemokines and opioids are often co-expressed in various tissues and
cells. The first interaction noted was in the immune system. Macrophages and
T-lymphocytes express opioid receptors (Chuang et al., 1994; Chuang et al.,
1995; Wick et al., 1996; Wybran et al., 1979) and these cell types also express
chemokine receptors. Because opioid agonists are often employed to control
inflammatory pain states, researchers sought to determine any effect that opioid
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treatment would have on immune system function. Chemotaxis achieved by the
chemoattractant gradient of chemokines is utilized by immune cells in order to
effectively move to their site of action. Therefore chemotaxis is often employed
as a functional test for cells of the immune system. Pretreatment with opioid
agonists reduces the chemotaxic response to chemokines (Chen et al., 2004;
Grimm et al., 1998; Choi et al., 1999; Rogers et al., 2000; Miyagi et al., 2000).
This reduction in chemotaxis is attributed to the heterologous crossdesensitization between opioids and chemokines (Chen et al., 2004; Grimm et
al., 1998; Szabo et al., 2002). Desensitization is utilized by GPCRs to regulate
the number of receptors that are available for ligand binding and receptor
activation. Desensitization occurs by phosphorylation of the GPCR following
ligand binding and receptor activation, this phosphorylation sterically hinders the
G-protein from binding to the receptor, thereby preventing downstream signaling
events from occurring following ligand binding to the receptor. All GPCRs share
this mechanism therefore this process can occur through two means: 1) a
receptor becoming phosphoralyted following its own activation, homologous
desensitization and 2) one GPCR in a cell being activated and causing
phosphorylation of other GPCRs within the same cell, heterologous
desensitization.
Another interaction between opioids and chemokines in the immune
system was discovered when a correlation was found among opioid abusers and
their susceptibility to HIV infection (Donahoe and Vlahov, 1998). This correlation
was long attributed to lifestyle choices of addicts, unprotected sex and sharing
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needles. However other explanations began to be considered when studies
demonstrated that morphine administration elevates HIV replication (Peterson et
al., 1990; Peterson et al., 1994; Chuang et al., 1993). Follow-up studies
discovered that this correlation could be attributed to the ability of opioid agonists
such as, morphine and DAMGO, to increase the expression of the chemokine
HIV co-receptors, CXCR4 and CCR5, on monocytes and lymphoblasts (Steele et
al., 2003; Miyagi et al., 2000). Increased chemokine expression on immune cells
essentially acts to increase the probability for viral entry/infection into cells.
As chemokines role in systems other than the immune system became
evident, possible interactions between opioids and chemokines in the nervous
system began to be explored. Several in vitro studies demonstrated that chronic
morphine treatment led to an upregulation of CCL2 in human neurons (Rock et
al., 2006), CCR2 and CCR5 in human astrocytes (Mahajan et al., 2005), and
MCP1 in astrocytes (El-Hage et al., 2006). These studies repeated what had
already been demonstrated in the immune system that opioid treatment leads to
changes in chemokine/receptor expression. Functional interactions within the
nervous system were also observed. Similar to the effect on chemotaxis in the
immune system, heterologous desensitization also occurs in the nervous system.
The Rogers and Adler group demonstrated chemokine injections into the
periaqueductal grey (PAG) leads to a decrease in the anti-nociceptive effects of
opioids (Szabo et al., 2002; Chen et al., 2007a; b). The chemokine induced
decrease in opioid anti-nociception was short, lasting only 2 hours following
chemokine administration (Szabo et al., 2002). These short term, acute effects
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were attributed to a heterologous desensitization mechanism, since changes in
expression pattern are unlikely to occur in the utilized time frame. Follow-up
studies demonstrated intra-PAG administration of chemokines RANTES and
SDF1 prior to systemic morphine injection is ineffective in decreasing the
analgesic effect of morphine (Adler et al., 2005). Chemokines ineffectiveness to
completely block the analgesic effects of systemically administered morphine can
be attributed to morphine acting on opioid receptors in both the central and
peripheral nervous system to carry out its analgesic effect, as outlined previously.
Heterologous desensitization between chemokines and opioids has also been
demonstrated on in vitro culture conditions of the DRG, in which chemokine
pretreatment led to a decrease in DAMGO induced calcium influx and decreased
MOR present on the plasma membrane (Zhang et al., 2004a). Current studies
have provided evidence of an interaction between chemokines and opioids
following acute administration and have attributed this acute interaction largely to
heterologous desenstization. However, the presence of chronic long lasting
interactions among these two signaling systems has yet to be demonstrated.
Chemokines/Receptors
Chemokines (chemotaxic cytokines) are a family of small proteins (10-14
kDa) traditionally thought to be involved in leukocyte trafficking under normal
physiological and pathological conditions, as well as signaling in the developing
and injured adult nervous system. Chemokines are typically classified by the
presence of a cysteine motif in the N-terminal region of the protein (Zlotnik and
Yoshie, 2000). Initial characterization of chemokines divided the family into α-

20

and β chemokines. In α chemokines, one amino acid separates the first two
cysteine residues (cysteine-X amino acid-cysteine or CXC), whereas in βchemokines, the first two cysteine residues are adjacent to each other (cysteine–
cysteine, or CC). Two additional classes were added for the chemokines,
lymphotactin (single cysteine, XC) and fractalkine (first two cysteines are
separated by three amino acids, CX3C). The chemokine nomenclature herein
utilizes both the original ligand name and the systematic name. The systematic
name uses XC, CC, CXC and CX3C, indicating the class to which the chemokine
belongs, followed by the letter ‘‘L’’ (for ligand) and then a number. The
numbering system corresponds to that already in use to designate the genes
encoding each chemokine. All chemokines exert their biological effects through
the activation of an extended family of seven transmembrane G-protein coupled
receptors (GPCRs). Nineteen chemokine receptors have been cloned including
six CXC receptors (CXCR1-7), 10 CC receptors (from CCR1-10) and two single
receptors each for lymphotactin (XCR1) and fractalkine (CXC3CR1). Chemokine
receptors are notoriously promiscuous, i.e. single chemokines can activate
several different chemokine receptors. There are, however, instances when a
chemokine receptor is uniquely activated by a single chemokine.
Stromal derived factor 1(SDF1) and CXCR4
Stromal derived factor 1 (SDF1) was first identified in 1993 from murine
bone marrow, hence the name (Li and Ransohoff, 2008; Tashiro et al., 1993).
SDF1 was given the new name of CXCL12 in accordance with the new
systematic naming system. SDF1 is highly conserved between mice and
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humans differing by only one amino acid, is widely expressed throughout the
body, and exhibits a broad range of actions affecting stromal cell migration,
leukocyte chemotaxis, vascularization of multiple organ systems, metastatic
tumor formation, neural development and chronic pain (reviewed in (Miller et al.,
2008; White et al., 2007). The molecular structure of SDF1 exhibits an amino
acid sequence that contains four cysteine residues conserved by most CXC
chemokines with the N-terminus of SDF1 particularly important for activity. The
monomer form of SDF1 is known to produce internalization of its receptor,
CXCR4, and intracellular calcium mobilization. Recent studies using nuclear
magnetic resonance structure analysis of the SDF1:CXCR4-N-domain complex
have also determined that the structural basis of the recognition of receptor
residues by the chemokine is indicative of a constitutively active dimeric form of
SDF1. Importantly, this dimeric form serves only to activate intracellular calcium
mobilization (Veldkamp et al., 2008). The differential effects on CXCR4-bearing
cells by either the monomeric or dimeric forms reveal the latter to be a potent
partial agonist (Veldkamp et al., 2008).
The receptor for SDF1 was identified from the orphan GPCR, LESTR/fusin
whose name was later changed to CXCR4 reflecting its ability to bind and
respond to SDF1 (Bleul et al., 1996; Oberlin et al., 1996). CXCR4 was also the
first identified co-receptor for human immunodeficiency virus (HIV-1) (Feng et al.,
1996). CXCR4 is a Gαi coupled GPCR capable of inducing calcium influxes
(Boutet et al., 2001; Gillard et al., 2002). The importance of SDF1/CXCR
signaling in nervous system development is continuing to be explored.
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SDF1/CXCR4 signaling importance in the development of the DRG was
demonstrated in CXCR4 -/- embryonic mice, which have small malformed DRGs
(Belmadani et al., 2005).
Until recently, CXCR4 was known to be the only receptor for SDF1. This
idea was challenged when the chemokine receptor, CXCR7, was shown to bind
SDF1 (Balabanian et al., 2005). Initially described as a scavenger receptor
(Boldajipour et al., 2008; Dambly-Chaudiere et al., 2007), more recent
interactions describe CXCR7 as possibly moderating the response of CXCR4 to
SDF1 by internalizing the ligand (Zabel et al., 2009). Although CXCR7 does not
elicit activation of G-protein signaling pathways, it does activate MAP kinases
through β-arrestin (Rajagopal et al., 2010).
AMD3100, a CXCR4 antagonist
AMD3100 is a bicyclam antagonist that was originally developed for the
treatment of HIV infection. It’s mechanism of action for HIV treatment being to
block viral binding to the HIV co-receptor CXCR4 and therefore limiting viral entry
(Schols et al., 1997; Donzella et al., 1998). AMD3100 selectively blocks viral
entry of R4 not R5 viral strains (Schols et al., 1997). Additional functional studies
of AMD3100 showed that AMD3100 blocked CXCR4 antibody labeling and
inhibited SDF1-induced calcium responses (Schols et al., 1997; Donzella et al.,
1998). AMD3100 has a 1000 fold greater affinity for CXCR4 over other
chemokine receptors, CXCR1-3, CCR1-9 (Hatse et al., 2002). An alternative
chemokine receptor target for AMD3100 was demonstrated at CXCR7, where
AMD3100 functions as an allosteric agonist (Kalatskaya et al., 2009). However,
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ongoing studies have demonstrated CXCR7 signals in a non-G-protein manner
(Rajagopal et al., 2010). Therefore AMD3100 agonist actions at CXCR7 should
be re-examined taking into account non-G protein signaling.
Chemokines and Pain
Immune and non-immune cells associated with the injury response
release pro-inflammatory mediators such as prostaglandins, histamine,
serotonin, protons, bradykinin, nerve growth factor, and pro-inflammatory
cytokines that can sensitize primary afferent neurons and contribute to pain
hypersensitivity. There is also adequate evidence demonstrating that like other
inflammatory mediators, chemokines elicit hypernociception. For example, Oh
and colleagues (2001) demonstrated that a single injection into the un-inflamed
adult rat hind paw of SDF1/CXCL12, Regulated upon Activation, Normal T-cell
Expressed, and Secreted (RANTES/CCL5) or macrophage inflammatory protein
1 (MIP1/CCL3) produces dose-dependent tactile allodynia. These behavioral
experiments in combination with accompanying RT-PCR, calcium imaging
studies and immunohistochemistry confirmed the presence and functionality of
the respective chemokine receptors, CXCR4, CCR5 and CCR4 in rodent dorsal
root ganglion (DRG) sensory neurons (Oh et al., 2001). Similar behavioral
effects were observed following the introduction of interleukin-8 (IL-8 CXCL8)
(Cunha et al., 1991) and intrathecal introduction of fractalkine (CX3CL1) (Milligan
et al., 2005). Studies conducted through intra- PAG injections of RANTES/CCL5
demonstrated a similar dose dependent decrease in rat tail flick latency
(Benamar et al., 2008a).
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Perhaps, the chemokine/receptor pairing that has been studied the most
extensively for its role in nociceptive behavior is MCP1/CCR2. The importance
of MCP1/CCR2 in neuropathic pain states was first demonstrated in CCR2
knockout mice. Testing of acute pain behavior in CCR2 knockout mice does not
differ from wild type mice. Following partial ligation of the sciatic nerve, a model
known to induce hypernociception, CCR2 knockout mice failed to display
mechanical hyperalgesia (Abbadie et al., 2003), while overexpression of glial
MCP1 by transgenic mice produced enhanced nociceptive responses (Menetski
et al., 2007). Additional confirmation of a de novo role for MCP1/CCR2 signaling
in injured neurons was observed following chronic compression of the dorsal root
ganglia (a model of spinal stenosis). In this investigation, the injury produced
neuronal upregulation of both MCP1 and CCR2 in the DRG while exogenous
administration of MCP1/CCL2 produced a depolarized resting membrane
potential and increased firing in the neuronal cell bodies (White et al., 2005).
Subsequent studies demonstrated that sensory neurons following peripheral
nerve injury exhibit chronic upregulation of functional MCP1/CCR2 signaling, an
a CCR2 selective receptor antagonist could reverse hypernociceptive behavior in
the injured animal (Bhangoo et al., 2007a). Further investigations into the
excitatory effects of MCP1/CCR2 signaling in sensory neurons have revealed
that i) regulation of the CCR2 chemokine receptor expression in neurons is
activity-dependent on the signal transcription factor, nuclear factor in activated T
cells (NFAT) (Jung and Miller, 2008) and ii) MCP1 activates a non-cation
selective voltage-independent, depolarizing current and inhibited a voltage
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dependent outward current (Sun et al., 2006). Moreover, MCP1 protein
expression by DRG neurons following nerve injury is colocalized with calcitonin
gene-related peptide in large dense core vesicles and release of MCP1 vesicles
could be induced from the soma by depolarization in a Ca2+-dependent manner
(Jung et al., 2008). The role of MCP1/CCR2 signaling is not limited to the DRG
soma. Zhang and De Koninick (2006) recently demonstrated that MCP1/CCL2 is
also present in central afferent fibers in the spinal cord. Electrical activity due to
peripheral nerve injury may serve to stimulate central afferent release of
MCP1/CCL2 into the spinal cord dorsal horn activating CCR2 bearing glial cells
or neurons (Abbadie et al., 2003; Zhang et al., 2007; Zhang and De Koninck,
2006).
A less extensively studied chemokine and receptor pairing for the
involvement in nociception is SDF1/CXCR4. SDF1 application to sensory neuron
cultures induces excitation and substance P release (Oh et al., 2001). This same
study demonstrated that hindpaw injection of SDF1 decreases paw withdrawal
threshold (Oh et al., 2001). Additionally, SDF1 injected into the PAG decreases
the analgesic ability of opioid and cannabinoid agonists (Szabo et al., 2002;
Benamar et al., 2008b). SDF1/CXCR4 signaling has been shown to be central to
chronic constriction injury (CCI) of the sciatic nerve (Dubovy et al., 2010) and the
nucleoside reverse transcriptase inhibitor, 2’,3’-dideoxycytidine (ddC)-induced
tactile nociceptive behavior (Bhangoo et al., 2007b).
Functional expression of chemokine/receptors in the damaged nervous
system may both participate in the etiology and symptomology of diverse
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pathological pain states. To date, the evidence in animal models includes the
upregulation of chemokine/receptors in partial ligation of the sciatic nerve
(Abbadie et al., 2003; Tanaka et al., 2004; Lindia et al., 2005; Zhang et al.,
2007), chronic constriction injury of the sciatic nerve (Milligan et al., 2004; Zhang
and De Koninck, 2006; Kleinschnitz et al., 2005; Dubovy et al., 2010), chronic
compression of the L4, L5 DRG (CCD; a rodent model of spinal stenosis) (White
et al., 2005; Sun et al., 2006), spinal cord contusion (Knerlich-Lukoschus et al.,
2008), chemically-induced focal nerve demyelination (Bhangoo et al., 2007a;
Jung et al., 2007), bone cancer pain (Vit et al., 2006), zymosan or adjuvantinduced inflammatory pain (Verge et al., 2004; Xie et al., 2006; Jeon et al., 2008;
Sun et al., 2007) and the chemotoxic effects of some anti-HIV therapeutics
(Bhangoo et al., 2007b). Despite the potential importance of these factors for
clinical pain syndromes, only a few studies have been designed to investigate the
presence of altered levels of chemokines. These include the measurement of
chemokine levels in prostatic secretion from individuals diagnosed with chronic
pelvic pain syndrome (Desireddi et al., 2008), herniated lumbar intravertebral
disc specimens (Ahn, 2002) and the cerebral spinal fluid taken (CSF) from
individuals diagnosed with chronic regional pain syndrome (CRPS) (Uceyler et
al., 2007; Alexander et al., 2007; Alexander et al., 2005). Although these studies
did not reveal a specific molecule that could serve as a diagnostic marker of a
chronic pain syndrome, it was notable that CSF from patients afflicted with CRPS
did reveal a common pattern of elevated cytokines and chemokines in 11 of 22
individuals tested (Alexander et al., 2007).
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Goals
In summary, the information outlined in the preceding sections has
demonstrated the need for a greater understanding of the mechanisms of opioid
induced hypernociception. The mounting evidence of the interaction between
opioids and chemokines in both the immune and nervous system, together with
numerous studies showing the role that chemokines play in nociceptive models
led me to pursue studies addressing the role that chemokines play in opioid
induced hypernociception. Furthermore, the peripheral nervous system, in
particular the DRG, has been overlooked in studies examining OIH. Providing
evidence about the interaction of opioids and chemokines in sensory neurons will
prove beneficial in developing new therapeutic options for opioid analgesics or
treatment options targeted at chemokine signaling.
In the first part, Chapter 2, of this project I set out to demonstrate an
upregulation of SDF1/CXCR4 signaling in the dorsal root ganglion though the
use of immunocytochemistry and in situ hybridization experiments in the DRG.
Calcium imaging studies were employed to test the presence of functional
chemokine receptors. Finally, CXCR4 antagonism was used to demonstrate
SDF1/CXCR4 signaling as a central component of OIH. The second part of this
project, Chapter 3, my focus was to determine whether opioid or non-opioid
receptor signaling was responsible for changes in SDF1/CXCR4 signaling
witnessed in morphine-induced hypernociception. I utilized a number of
pharmacological compounds to dissect the opioid and non-opioid receptor
signaling components of OIH. These studies also employed the use of
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immunoctyochemisty techniques to examine changes in the expression of
CXCR4 in the rodent DRG. Calcium imaging studies were used to test for the
presence of functional chemokine receptors. CXCR4 antagonism was again
utilized to determine the involvement of SDF1/CXCR4 signaling in any behavior
induced by each of the pharmacological agents that were employed. The results
of these experiments provide evidence of SDF1/CXCR4 signaling in opioid
induced hypernociception and provide further details about the mechanisms
behind opioid induced hypernociception.

CHAPTER TWO
THE ROLE OF SDF1/CXCR4 SIGNALING IN MORPHINE-INDUCED
HYPERNOCICEPTION
Overview
Morphine and related compounds are the first line of therapy in the treatment of
moderate to severe pain. Over time, individuals taking opioids can develop an
increasing sensitivity to noxious stimuli, even evolving into a painful response to
previously non-noxious stimuli (opioid-induced hypernociception; OIH). The
mechanism underlying OIH is not well understood although complex intracellular
neural mechanisms, including opioid receptor desensitization and downregulation, are believed to be major mechanisms underlying OIH. However, OIH
may also be associated with changes in gene expression. A growing body of
evidence suggests that cellular exposure to mu agonists upregulate
chemokines/receptors and recent work from our lab implicates chemokine
upregulation in a variety of neuropathic pain behaviors. Here we characterized
the degree to which chemokines/receptors signaling is increased in primary
afferent neurons of the dorsal root ganglion (DRG) following chronic morphine
sulphate treatment and correlated these changes with tactile hypernociceptive
behavior in rodents. We demonstrate that mRNA expression of the chemokine,
29
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stromal-derived factor 1 (SDF1/CXCL12) is upregulated following morphine
treatment in sensory neurons of the rat. The release of SDF1 was found to be
constitutive when compared with the activity dependent release of the C-C
chemokine, monocyte chemoattractant protein 1 (MCP1/CCL2) in a line of F-11
neuroblastoma-sensory neuron hybrid cells. We further determined that there is
pronounced CXCR4 expression in satellite glial cells, and following morphine
treatment, increased functional CXCR4 expression in sensory neurons of the
DRG. Moreover, intraperitoneal administration of the selective CXCR4
antagonist, AMD3100, completely reversed OIH in the rat. Taken together; the
data suggest that opioid-induced SDF1/CXCR4 signaling is central to the
development of long lasting OIH and that receptor antagonists represent a
promising novel approach to the management of the side effects associated with
the use of opioids for chronic pain management.
Background
Opioids such as morphine currently represent the best option for the
management of moderate to severe trauma induced, perioperative and cancer
pain. Opioid compounds are also increasingly being used for non cancer
associated chronic pathological pain. However, prolonged administration of
opioids is associated with significant problems including the development of antinociceptive tolerance, wherein higher doses of the drug are required over time to
elicit the same degree of analgesia. Repeated administration of higher doses of
morphine or fentanyl also results in increasing pain sensitivity, a syndrome
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clinically known as opioid-induced hypernociception (OIH) (Angst et al., 2003;
Arner et al., 1988; Singla et al., 2007). This increased pain is usually experienced
at different locations from the original site of injury (Ossipov et al., 2004).
While it is thought that opioids modulate tactile hypernociception solely by
acting at neuronal opioid receptors, administration of chronic morphine is also
known to induce a rapid increase in the expression of proinflammatory cytokines
such as TNFα, IL1β and IL-6 in a number of cell types within the nervous system
(Johnston et al., 2004). These proinflammatory cytokines are powerful pain
enhancing proteins that may, in turn, suppress acute opioid analgesia and
contribute to the apparent loss of opioid analgesia upon repeated opioid
administration (“tolerance”) (Hutchinson et al., 2008). The family of pronociceptive cytokines includes chemotactic cytokines (chemokines). Proalgesic
effects of chemokines have been implicated in both acute and chronic tactile
hypernociceptive behavior (Abbadie et al., 2003; Bhangoo et al., 2007a;
Bhangoo et al., 2007b; Johnston et al., 2004; Jung et al., 2009; Menetski et al.,
2007; Milligan et al., 2004; Oh et al., 2001; Wang et al., 2008; White et al., 2005;
Xie et al., 2006). However, the degree to which chronic morphine treatment
alters gene expression of chemokines and their receptors, and whether this
contributes to syndromes such as OIH is unknown.
Effects of opioids on chemokine receptor expression are potentially important
determinants of HIV-1 infection rates among intravenous drug users, as the
chemokine receptors CCR5 and CXCR4 are co-receptors for the HIV-1 virus coat
protein, gp120. To this end a number of studies using chronic morphine or the
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selective µ opioid agonist, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)
produce increased expression of monocyte chemoattractant protein-1
(MCP1/CCL2), regulated upon activation normal T-cell expressed and secreted
(RANTES/CCL5), and their respective receptors, CCR2 and CCR5, in astrocytes
and neurons via largely unknown mechanisms (Avdoshina et al., 2010; Mahajan
et al., 2005; Rock et al., 2006). A similar study demonstrated that DAMGO
substantially increased the expression of both CCR5 and CXCR4 in leukocytes
(Steele et al., 2003). Taken together, these observations raise the possibility that
repeated exposure to opioids and subsequent increases in chemokine receptor
signaling might also be central to OIH.
We now demonstrate that many nociceptive neurons express functional
receptors for a number of chemokines following systemic injection of morphine.
Chemokine receptor signaling via the CXCR4 receptor may be central to OIH as
the administration of the selective CXCR4 receptor antagonist, AMD3100,
transiently reversed OIH in rats. Collectively, the data suggest that chemokine
receptor antagonists represent a promising novel approach to the management
of the side effects associated with long term opioids for chronic pain control.
Methods
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard
rodent chow and water available ad libitum. Experiments were performed during
the light cycle. These experiments were approved by the Institutional Animal
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Care and Use Committee of Loyola University, Chicago and Indiana
University/Purdue University in Indianapolis. All procedures were conducted in
accordance with the Guide for Care and Use of Laboratory Animals published by
the National Institutes of Health and the ethical guidelines of the International
Association for the Study of Pain. All animals were randomly assigned to either
treatment or control groups.
Drugs and method of administration The drugs, morphine sulfate salt and the
bicyclam, AMD3100, were employed in this study. Morphine sulfate salt and
AMD3100 were purchased from NIDA Drug Supply Program (Rockville, MD) and
Sigma-Aldrich (St. Louis, MO), respectively. All drugs were freshly prepared in
saline on the day of the experiment. Morphine sulfate- and vehicle-treated groups
were given intraperitoneal (i.p.) injections once daily for 5 days of 10 mg/kg or
saline (vehicle). After tactile hypernociception was established, animals were
given an i.p. injection of AMD3100 (10 mg/kg) (Fig. 3). Previous nociceptive
behavioral studies from our lab using AMD3100 at doses of (1, 5, 10, and 25
mg/kg) observed: no reversal of effect with 1 mg/kg, partial inconsistent effect
with 5 mg/kg, reversal with 10 mg/kg, and reversal with side effects at 25 mg/kg
(unpublished observations). Therefore, 10 mg/kg AMD3100 was selected for
these studies.
Tactile Behavioral assessment Von Frey filaments were used to test
mechanical sensitivity before, during and after cessation of morphine sulfate
administration. Prior to initial von Frey tactile testing, all rodents were habituated
to testing chambers for at least two days. Animals were tested for baseline
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responses (BL) at least two times before undergoing the repeated morphine
sulfate treatment (10 mg/kg, i.p. daily). Mechanical testing with von Frey
filaments during the morphine sulfate dosing paradigm was limited to injection
day (ID) 3. Behavioral assessment on ID3 occurred 18-20 hours after the ID2
morphine administration and before ID3 morphine or vehicle treatment (Fig. 3).
Additional behavioral assessment following drug or vehicle administration
occurred on post-injection day (PID) 1, 2, 3, 7, 14, 21, and 28. All behavioral
testing was performed by laboratory assistants who were blinded to the
experimental conditions and unfamiliar with the experimental aims.
The incidence of foot withdrawal in response to mechanical indentation of
the plantar surface of each hindpaw was measured with a von Frey filament
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots
are representative of the distal nerve distributions of saphenous, tibial and sural
nerves (medial to lateral) in the glabrous hindpaw. During each test, the rodent
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm
openings. The cage is elevated so that stimulation can be applied to each hind
foot from beneath the rodent. The filaments were applied in order of ascending
force. Each filament was applied alternately to each foot and to each locus. The
duration of each stimulus was approximately 1 s and the inter-stimulus interval
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a
percentage of the 6 applications of each stimulus and the percentage of
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withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et
al., 2003). The von Frey withdrawal threshold was defined as the force that
evoked a minimum detectable withdrawal observed on 50% of the tests given at
the same force level. For cases in which none of the specific filaments used
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to
define the threshold.
Foot withdrawal to thermal stimulus To evaluate the paw withdrawal threshold
(PWT) to thermal stimulation, the Hargreaves’ plantar test apparatus was used
(Ugo Basile, Varese, Italy). Rats were placed on a 2-mm-thick glass floor; a
mobile infrared heat generator with an aperture of 10 mm was aimed at the rat’s
hind paw under the floor. Following activation of the heat source (IR setting = 70),
the reaction time (the withdrawal latency of the hindpaw) of the rat was recorded
automatically. A shortening of the withdrawal latency indicated thermal
hypernociception. The temperature of the glass floor was kept at 22.5–23.5 °C.
Measurements of the withdrawal latency of the paw began after the rats were
habituated to the testing environment. Animals were habituated to the testing
apparatus each testing day for approximately 30 minutes. Five trails of thermal
measurements were taken, at 5 min intervals, on each hind paw, and the initial
pair of trial measurements was not used. The averages of the three remaining
pairs of measurements taken were employed as data. Baseline recordings were
taken 2-3 days prior to initiation of morphine dosing paradigm. Thermal behavior
was measured on during dosing paradigm (ID4) and following the cessation of
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the dosing paradigm (PID 3-9). The effect of the CXCR4 antagonist, AMD3100,
on thermal behavior was determined PID7.
Assessment of Withdrawal Behavior Withdrawal behaviors were monitored by
a trained observer for each rat 1 min every 10 min over a 30-min period.
Measurements recorded included locomotion: jumping, wet dog shakes, tremor,
ptosis, and piloerection. The number of counts for each behavior over the 30
minute period was recorded and the average count among the treated animals
was used as the data for each time point. Weight was also monitored during the
testing period. Baseline recordings (BL) were taken for 2 days prior to initiation
of morphine dosing paradigm. Withdrawal behavior was recorded following the
cessation of morphine dosing paradigm (PID 1-8). The effect of the CXCR4
antagonist, AMD3100, on thermal behavior was determined PID7.
Tissue processing and immunocytochemistry for neural tissue. Morphine or
control treatments rats’ lumbar (L3-L6) DRG tissue was collected after animals
were sacrificed and transcardially-perfused with saline followed by fixative. Fixed
tissue was then embedded for sectioning and processed using
immunocytochemical methodologies commonly used in this lab (Bhangoo et al.,
2007a). Tissue sections from L4 and L5 were used in immunocytochemical
experiments. Tissue sections were blocked with natural horse serum blocking
buffer (SuperBlock® Blocking Buffer in PBS (Thermo Scientific, Rockford, IL,
Natural Horse Serum (3% v/v), Triton X (0.4% v/v)). Primary antisera used was
the anti-CXCR4 rat monoclonal antibody, 2B11 (1:20,000 dilution; BD
Biosciences, San Jose, CA) which binds to both human and mouse CXCR4
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(Forster et al., 1998; Schabath et al., 1999). CXCR4 anti-body was dissolved in
blocking buffer and incubated overnight. After primary incubation, slides were
incubated in secondary antibodies (1:1000 dilution; anti-rat made in donkey
conjugated to CY3, Jackson ImmunoResearch, West Grove, PA).
Images were collected with a DeltaVision microscope (Applied Precision)
equipped with a digital camera (CoolSNAP HQ; Photometrics), using a 1.4numerical aperture (NA) 20x objective lens, and were deconvolved with
SoftWoRx deconvolution software (Applied Precision).
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6
DRGs were acutely dissociated using methods described by Ma and LaMotte
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naive or
morphine-treated animals four to six days following the last morphine injection.
The DRGs were treated with collagenase A and collagenase D in HBSS for 20
minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN), followed by
treatment with papain (30 units/ml, Worthington Biochemical, Lakewood, NJ) in
HBSS containing .5 mM EDTA and cysteine at 35°C. The cells were then
dissociated via mechanical trituration in culture media containing 1 mg/ml bovine
serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis MO). The culture
media was Ham's F12 mixture, supplemented with 10% fetal bovine serum,
penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2 (Life Technologies).
The cells were then plated on coverslips coated with poly-L lysine and laminin (1
mg/ml) and incubated for 2-3 hours before more culture media was added to the
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wells. The cells were then allowed to sit undisturbed for 12–15 hours to adhere at
37°C (with 5% CO2).
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was
placed onto the inverted microscope. Intracellular calcium was measured by
digital video microfluorometry with an intensified CCD camera coupled to a
microscope and MetaFluor software (Molecular Devices Corporation,
Downington, PA). Cells were illuminated with a 150 W xenon arc lamp, and the
excitation wavelengths of the fura-2 (340/380 nm) were selected by a filter
changer. Sterile solution was applied to cells prior to chemokine application, any
cells that responded to buffer alone were not used in chemokine responsive
counts. Chemokines were applied directly into the coverslip bathing solution. If
no response was seen within 1 minute, the chemokine was washed out. For all
experiments, MCP1, SDF1, regulated upon activation, normal T cell expressed
and secreted (RANTES/CCL5), and interferon-gamma-induced protein
(IP10/CXCL10) were added to the cells in random order, after which capsaicin
(3nM), high K+ (50µM) and ATP (3nM) were added. The chemokines used were
purchased from R & D Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the
protein by the LAL method), and all were used at a concentration of 100 nM to
ensure maximal activation (Bhangoo et al 2007a; Bhangoo et al 2007b).
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Chemokines were reconstituted in sterile 0.1%BSA/PBS, and aliquots were
stored at -20°C. Calcium imaging traces were analyzed by two independent
analyzers and only responses that were in agreement between two individuals
were used in the counts.
In situ hybridization. In situ hybridization histochemistry for chemokine
receptors was performed using digoxigenin-labeled riboprobes. Treated and nontreated rodents were sacrificed using carbon monoxide. Lumbar DRGs from the
injected and control animals were rapidly removed, embedded in OCT compound
(Tissue Tek, Ted Pella, Inc., Redding, CA) and frozen. L4 and L5 DRG sections
were cut serially at 12

m. The SDF1 probes were generated as described

previously (Lu et al., 2002). Signals were visualized by using NBT/BCIP reagents
(Roche Applied Science, Indianapolis, IN) in the dark for 2–20 h depending upon
the abundance of the RNA. The in situ image was captured using a Retiga EX
charge-coupled device camera (Q-imaging, Burnaby, BC).
Plasmid construction. To make chemokine-fluorescent protein fusion
constructs, MCP1 and SDF1-alpha protein coding sequence was cloned into
pEGFP-N1 or pmCherry-N1 (Clontech).
F11 Culture Conditions. F11 cells (a mouse N18TG2 neuroblastoma X rat DRG
sensory neuron hybrid cell line) were grown as monolayers either in 100-mm
plastic dishes under 5% CO2 in Ham’s F-12 medium supplemented with 20%
fetal bovine serum (Hyclone), 100 pM hypoxanthine/ 1 pM aminopterin/ l2 pA4
thymidine, and 50 IU/ml of penicillin/streptomycin. Cells were fed every other day
for several days preceding an experiment with Ham’s F- I2 medium
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supplemented with 1% fetal bovine serum, 50 ng/ml of NGF, 2 pM retinoic acid,
0.5 mM dibutyryl cyclic AMP, 10 pM3-isobutyl-I-methylxanthine (IBMX), a 1:500
dilution of 2.5 mg/ml of bovine insulin, a 1:100 dilution of 10 mg/ml of transferrin,
and 50 IU/ml of penicillin/streptomycin.
Enzyme-linked immunosorbant assay (ELISA). Constitutive and regulated
release of MCP1-RFP (mCherry) and SDF1-RFP (mCherry) was measured by
sandwich ELISA. F11 DRG neuronal cells were transfected with MCP1-RFP or
SDF1-RFP. 24 h after the transfection, cells were placed under differentiating
conditions and allowed to differentiate for 48 h. When cells were fully
differentiated, culture medium was replaced with balanced salt solution (BSS)
containing either 5 mM (normal) or 50 mM KCl (depolarizing). Normal BSS (145
mM NaCl, 5 mM KCl, 2 mM CaCl2,1 mM MgCl2) and depolarizing BSS (100 mM
NaCl, 50 mM KCl, 2mM CaCl2, 1mM MgCl2) had the same osmolarity. After 30
min, released MCP1-RFP or SDF1-RFP was measured from supernatant by
sandwich ELISA. A polyclonal anti-RFP antibody (Abcam ab34771) was used as
the capture antibody (1:50,000). Chemokine-specific antibodies were used as
the detecting antibodies: for SDF1, a mouse monoclonal anti-SDF1 antibody
(Santa Cruz sc-74271); for MCP1, a goat polyclonal antibody (Santa Cruz sc1785).
Statistics. Data for sandwich ELISA were presented as mean ± SEM and
analyzed by one way ANOVA followed by Newman-Keuls multiple comparison
tests. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical
significance of differences in the mean threshold forces for foot withdrawal to
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punctate indentation as a function of time and between experimental groups by
means of repeated measures analyses of variance (RMANOVA) followed by post
hoc pairwise comparisons (Tukey method). Statistical significance was set at
p < 0.05. GraphPad Software (LaJolla, CA) was used to determine the statistical
significance of differences in calcium response among naïve and treatment
groups using Chi-square test with Yates correction with p<0.05 set as statistical
significance.
Results

Figure 3. Repeated morphine treatment paradigm. Animals underwent
baseline testing for 2-3 days prior to the start of injections. Rats received
once daily i.p. injections of morphine (10 mg/kg) for 5 days. Behavioral
testing that occurred during the 5 days of injections (ID) were carried out 24
hours after the last morphine injection. Following the injection period,
behavior was conducted on animals for up to 28 days following the last
morphine injection (PID). Behavioral testing with the CXCR4 antagonist,
AMD3100, occurred five days after the last morphine injection (PID5).

Repeated morphine treatment leads to tactile hypernociception
Initial experiments were conducted in order to determine the ability of our
morphine dosing paradigm to induce nociceptive behavior as measured by tactile
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and thermal assessment. Tactile hypernociception as measured by von Frey
filaments is a characteristic behavioral response that develops in rodents
following repeated administration of morphine (Celerier et al., 2000; Gardell et
al., 2002). Our behavioral assessment of tactile hypernociception was performed
prior to the start of the injection paradigm, during the 5 day dosing regimen, and
for 28 days following the repeated morphine treatment paradigm (Fig.4). In our
experiments, the mean paw withdrawal threshold (PWT) of the tested hind paws
exhibited a decrease after only two daily morphine injections relative to preinjection baseline PWT (ID3; 70.5±2.1 mN to 35.1±2.9 mN; n=12; p<0.0001).
Statistically significant decreases in PWT were maintained until at least PID28
(Fig. 2).
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Figure 4. Repeated morphine treatment (10 mg/kg for 5 days) results in the
development of tactile hypernociception as measured by von Frey filaments.
Tactile hypernociceptive behavior persists for at least 28 days following the last
morphine injection. ID, injection day, PID, post injection day (Repeated
Measures ANOVA; *p<0.05, significant difference from baseline). (n=6)

The changes in PWT observed at ID3 suggest that this nociceptive
behavior is unaffiliated with morphine withdrawal signs such as jumping or wet
dog shakes. Opioid withdrawal behaviors were observed between 24-48 hours
following the last morphine injection and continued to be measured for 9 days
following the cessation of the morphine dosing paradigm. Alterations in the paw
withdrawal latency evoked by thermal stimulation were not observed with this
dosing paradigm (Fig. 5).
These experiments demonstrated our repeated morphine dosing paradigm
is able to induce tactile nociceptive behavior that persists for at least 28 days
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following the last morphine injection. However, thermal nociceptive behavior was
not observed.

Figure 5. Thermal nociceptive behavior does not develop following
repeated morphine treatment. Thermal behavior, latency to withdrawal
hindpaw, as measured by Hargreaves’ plantar test apparatus is
unchanged over the entire testing period. BL, Baseline, ID, injection day,
PID, post injection day (n=8)

Repeated morphine treatment decreases CXCR4 immunoreactivity in the
rat DRG.
To assess the changes in CXCR4 expression in the rodent DRG following
repeated morphine administration, immunocytochemistry experiments were
conducted on DRG tissue sections using an antibody against the CXCR4
receptor.
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The CXCR4 antibody binds the N-glycosylation site g1 of human CXCR4.
Although this site does not influence HIV-1 coreceptor function (Huskens et al.,
2007), this antibody is an effective neutralizing antibody in tumor formation and
angiogenesis (Katoh and Katoh, 2010). In the adult rat dorsal root ganglia (DRG),
CXCR4 expression is largely limited to presumptive nonmyelinating satellite glial
cells (SGCs) of the DRG based on anatomical locale (Fig. 6A). In addition to the
SGCs, an occasional neuron was also observed to express the CXCR4. This
expression pattern in the DRG coincides with CXCR4 mRNA expression pattern
seen previously (Bhangoo et al 2007). By comparison, very few CXCR4immunoreactive, nonmyelinating SGCs were evident following repeated
morphine treatment at PID5 (Fig. 6B). By PID21, CXCR4 immunoreactivity (-ir) in
the nonmyelinating SGCs of the morphine treated rats was again evident (Fig.
6C). Concurrent with return of CXCR4-ir, SGCs in the DRG at PID21 was the
gradual return of PWT to pre-treatment BL thresholds (Fig. 4).
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Figure 6. Repeated morphine injections reduces CXCR4-immunoreactivity (-IR) in
satellite glial cells of rat lumbar DRG sections. Animals received repeated
morphine injections (10 mg/kg for 5 days) and tissue was collected at 5 days
(PID5) and 21 days (PID21) after the last morphine injection. A) CXCR4-IR (red)
is largely restricted to satellite glial cells in the naïve rodent DRG. B) Following
repeated morphine treatment, CXCR4-IR is reduced at PID5. C) By PID21
CXCR4-IR begins to return to naïve levels. Scale bar is 100 m (n = 7 for day 5
and n = 7 for each day 21).

SDF1 mRNA is increased in sensory neurons following repeated morphine
treatment and the protein is tonically released.
Given the apparent decline of CXCR4-ir in the DRG following the repeated
morphine treatment paradigm, we determined whether SDF1 mRNA expression
in the lumbar DRG was also altered by the dosing paradigm. We observed
cellular expression patterns of SDF1 mRNA transcripts by in situ hybridization
using digoxigenin-labeled riboprobes in relatively few cells of the saline-treated
DRG (Fig. 7A). Following repeated morphine treatment both non-neuronal cells
and numerous sensory neurons exhibited SDF1 mRNA transcripts (Fig.7B).
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Figure 7. SDF1 mRNA expression is increased in the lumbar DRG following
repeated morphine exposure. In situ hybridization was used to assess the expression
pattern of SDF1 mRNA. A) High power photomicrograph of basal expression of SDF1
mRNA was observed in the lumbar DRG from saline injected rats in non-neuronal
cells (black arrowhead indicates SDF1 mRNA transcripts in non-neuronal cell). Teal
arrows indicate a lack of neuronal SDF1 mRNA transcripts. After a repeated
morphine exposure, the level of SDF1 mRNA expression increased by post-injection
day (PID) -5. SDF1 mRNA expression appears in both neuronal and non-neuronal
cells. (Black arrows indicate neurons positive for SDF1 mRNA transcripts;
arrowheads, presumptive glial cells positive for SDF1 mRNA transcripts). Scale bar A
and B is 50 μm (n = 5 for each condition).

The observation that SDF1 is expressed in DRG neurons following
repeated morphine treatment raises the possibility that the ligand may be
tonically released from these cells. Hosung Jung from Dr. Richard Miller’s lab
therefore examined the release of SDF1 using the F11 cell line. This cell line was
derived from DRG neurons and maintains many of the differentiated properties of
these cells (Platika et al., 1985). We compared the characteristics of SDF1
release to those of MCP1/CCL2, another chemokine that has been shown to be
expressed and released by DRG neurons (Jung et al., 2008). Following the
expression of chemokine fluorescent fusion proteins (SDF1-RFP and MCP1-
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EGFP) we noted that the two chemokines localized to different sets of secretory
vesicles (Fig. 8). We measured constitutive and K+ depolarization induced
release of each chemokine from F11 cells using a sandwich ELISA, and
observed that the patterns of release for the two chemokines were also different.
Release of MCP1-RFP from differentiated F11 cells was significantly increased
by depolarizing medium containing high K+ (Fig 9A). However, the release of
SDF1-RFP was quite apparent under non depolarizing conditions and was not
increased further by K+ depolarization (Fig 9B), suggesting that most SDF1
release was constitutive whereas a significant portion of MCP1 release was
regulated by neuronal depolarization. This result implies that once the expression
of SDF1 has been increased in DRG neurons (see Fig 7); it will be constitutively
released from these cells.
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Figure 8. MCP1 and SDF1 are sorted into different pools of vesicles in F11 cells. (A)
MCP1-RFP (left panel), SDF1-RFP (right panel), or RFP alone was transfected into
F11 cells. After 2 days, MCP1-RFP or SDF1-RFP was detected from the cell lysate by
Western blot analyses using antibodies against MCP1, SDF1, and RFP. The precursor
form (**) as well as the mature form, (*) in which the signal peptide has been cleaved,
could be detected both by the RFP antibody and the chemokine antibodies (MCP1 or
SDF1), indicating that the fusion of RFP to the C-termini of MCP1 and SDF1 does not
alter their processing into the secretory pathway. (B) MCP1-EGFP was cotransfected
with RFP alone (top panels), MCP1-RFP (middle panels), or SDF1-RFP (bottom
panels). Unlike RFP alone which diffusively localized throughout the cell including the
nucleus, MCP1-RFP and SDF1-RFP both exhibited perinuclear localization and
punctate subcellular localization reminiscent of secretory vesicles. MCP1-EGFP and
SDF1-RFP did not colocalize (bottom panels) unlike MCP1-EGFP and MCP1-RFP
(middle panels), indicating that MCP1 and SDF1 are packaged into different pools of
secretory vesicles.
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Figure 9. Chemokine specific release from transfected F11 cells is by regulated
(MCP1) or constitutive release mechanisms (SDF1). F11 DRG neurons were
differentiated and then depolarized by high K stimulation (50 mM; 50K), either with
or without extracellular Ca (2 mM or 0 mM; 2Ca or 0CA). The amount of MCP1RFP released into the culture medium was measured by sandwich ELISA. The
release of SDF1-mRFP1 was examined in the same manner as MCP1-mRFP1.
Baseline levels of MCP1-RFP (A) or SDF1-RFP (B) in F11 cells prior to addition of
50mM K were 6.3 ± 0.7 or 10 ± 1.1% of total media, respectively (A sandwich
ELISA; *p<0.01 vs. any other group, Newman-Keuls Multiple Comparison Test).

Repeated morphine treatment increases functional chemokine receptor
expression by capsaicin sensitive DRG neurons.
To further investigate the status of functional CXCR4 receptor expression in
the DRG following repeated morphine treatment, we utilized Ca2+ imaging
studies in acutely dissociated DRGs derived from animals subjected to repeated
morphine conditions and naive controls. The time points used corresponded to
time points used for immunohistochemical and behavioral assessment (Fig 6).
The acutely dissociated DRG preparations were categorized into three neuronal
and non-neuronal cell types: non-capsaicin sensitive neurons (high K and ATP
responsive), capsaicin sensitive neurons (capsaicin, high K, and ATP
responsive), and glia (ATP responsive only). These cell response criteria were
chosen strictly as an indicator of the types of cells that may be affected by the
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repeated morphine treatment paradigm. The tested chemokines were selected
so as to activate a wide spectrum of chemokine receptors known to be
expressed by neurons and non-neuronal cells (CXCR4-SDF1/CXCL12, CXCR3IP10/CXCL10, CCR2-MCP1/CCL2, CCR5-RANTES/CCL5). The chemokine
concentration used for these experiments were based on their maximally
effective concentrations using our previous observations on acutely dissociated
DRGs (Bhangoo et al., 2007a; Bhangoo et al., 2007b).
Naïve

SDF1
IP-10
MCP1
RANTES

Noncapsaicin
sensitive
neurons
7%
(6/85)
4%
(3/85)
4%
(3/85)
14%
(12/85)

Capsaicin
-sensitive
neurons
7%
(5/72)
0%
(0/72)
6%
(4/72)
4%
(6/72)

Morphine-Treated

Glia
21%
(9/44)
2%
(1/44)
9%
(4/44)
21%
(9/44)

Noncapsaicin
sensitive
neurons
15%
(17/112)
13%
(14/112)*
16%
(18/112)**
17%
(19/112)

Capsaicinsensitive
neurons
34%
(25/73)**
25%
(18/73)**
29%
(21/73)**
29%
(21/73)**

Glia
27%
(13/49)
8%
(4/49)
25%
(12/49)
12%
(6/49)

Table 2. Repeated morphine treatment increases nociceptive neurons
chemokine calcium responsiveness. Daily morphine injections (10 mg/kg for 5
days) were administered to animals. Lumbar DRGs were acutely dissociated
from these animals 4-6 days following the last morphine injection. The most
significant increase in chemokine calcium responsiveness occurred in the
nociceptive neurons (** p<0.01, * p<0.05, Chi-square with Yates correction).
(naïve, n=8, morphine-treated n=6)

Application of all tested chemokines produced [Ca2+]i changes in small
numbers of neuronal and non-neuronal populations of cells derived from control
DRGs (Table 2). Following exposure to repeated morphine treatment, we
observed a significant increase in the chemokine responsiveness of non-
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capsaicin sensitive and capsaicin sensitive neurons. This included a robust
increase in SDF1 responsive capsaicin sensitive neurons (p<0.0001). Hence it
appears that DRG nociceptive neurons express more functional chemokine
receptors, including CXCR4 receptors, following the repeated morphine
treatment paradigm (Table 2).
Reduced CXCR4 expression following repeated morphine treatment is
abolished by AMD3100 treatment
Given that tonic activation of CXCR4 by SDF1 leads to internalization of both
chemokine and receptor (Burger and Kipps, 2006), it is entirely possible that the
constitutive release of neuronal SDF1 and subsequent neuronal signaling via
CXCR4 may result in diminished evidence of CXCR4-ir in the sensory ganglia of
morphine treated rats (Fig 100C). This event would not be unlike previous
reports in the dentate gyrus (Bhattacharyya et al., 2008; Kolodziej et al., 2008).
Additional studies have shown that the binding capabilities of the CXCR4
antibody utilized for these studies can compete with SDF1 binding sites
(Dubeykovskaya et al., 2009). To test this possibility we intraperitoneally
administered the CXCR4 antagonist, AMD3100, at doses of 1 and 10 mg/kg and
sacrificed the animals one hour later. Overall increases in CXCR4-ir binding
were observed following AMD3100 administration in morphine treated animals at
10 mg/kg (Fig. 10E), but not 1 mg/kg (Fig. 10D). As evidence of the de novo
SDF1 signaling via CXCR4, CXCR4-ir was also observed in numerous neurons
(Fig. 10E). This data provides further support for the increased functional
CXCR4 receptors observed in neurons (see Table 2). Three hours after
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AMD3100 administration, the CXCR4-ir was again qualitatively decreased in the
DRG (Fig. 10F). Following administration of AMD3100 in the naïve animal (Fig.
10B), there was a noticeable decrease in CXCR4-ir when compared with the
naïve animal (Fig. 10A). This is likely attributed to the competition that exists
between AMD3100 and CXCR4 antibody for available receptor binding sites.
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Figure 10. The CXCR4 antagonist AMD3100 reverses loss of CXCR4
immunoreactivity in DRG derived from repeated morphine treated rats. Untreated rats
(A), naive animal administered AMD3100 1 hour before sacrifice (B), repeated
morphine treatment alone (i.p., 10 mg/kg, once daily for 5 days) (C) repeated
morphine treatment in combination with different doses of AMD3100 1 hour before
sacrifice (D, E) and 3 hours before sacrifice (F). Treatment with AMD3100 reverses
repeated morphine treatment-induced loss of CXCR4 immunoreactivity at PID5 (C) in
a dose-dependent manner (D,E). CXCR4-immunoreactivity (red label) in rat DRG
sections following 10 mg/kg (E), but not 1 mg/kg (D) dose of AMD3100 returns
CXCR4 immunoreactivity to levels observed in untreated control rats (A). White
arrows indicate the presence of CXCR4-immunopositive neurons following AMD3100
treatment. Scale bar is 100 m. (n=4 each group)

Decreased tactile hypernociception following intraperitoneal injection of
CXCR4 antagonist, AMD3100.
To determine whether SDF1/CXCR4 signaling was involved in OIH, we
administered a single systemic dose of either vehicle or 10 mg/kg AMD3100 i.p.
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at PID5. Systemic injection of AMD3100 (10 mg/kg) in naïve rodents did not alter
baseline PWT (70.5±2.1 mN; Fig 11). Vehicle injections in morphine treated rats
did not alter PWT (data not shown). However, 1 hour after AMD3100 was
administered to morphine treated rats, PWT returned to baseline (69.25±2.75
mN; p<0.01). The rapid onset of AMD3100 was short lived as PWTs returned to
pre-dosing levels by three hours (35.25±4.59 mN) (Fig 11). The return of
morphine-induced behavior 3 hours post AMD3100 injection coincides with the
returned loss of CXCR4-ir observed 3 hours post AMD3100 injection in rat DRG
sections (Fig 10F).
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Figure 11. Morphine-induced tactile hypernociception in rodents is transiently
reversed with CXCR4 antagonist, AMD3100 treatment. Five days following
the last morphine injection (PID5) rats received an i.p. injection of AMD3100
(10 mg/kg) and tactile behavior was measured by von Frey filaments 1 and 3
hours post injection. AMD3100 treatment completely reversed morphineinduced tactile hypernociception by one hour post injection. Tactile
hypernociception returned 3 hours following injection of AMD3100.
*Significant difference from baseline; one-way ANOVA; p<0.01).(n=6)

Discussion
The experiments reported here demonstrate that following repeated
morphine exposure, rodents exhibited a prolonged tactile hypernociception. This
change in paw withdrawal threshold was maintained at least until PID28.
Importantly, morphine-induced tactile hypernociception could be transiently
reversed by a chemokine receptor antagonist that is selective for CXCR4
receptors. These results provide the first demonstration that morphine induced

57

tactile hypernociception behavior in the rodent appears to be dependent on
activation of CXCR4 receptors. Thus, morphine induced SDF1 signaling via
CXCR4 receptors appears to change the balance between opioid analgesia and
hypernociception.
OIH has been observed both clinically (Angst et al., 2003; Arner et al.,
1988; Singla et al., 2007) and experimentally (Laulin et al., 1999; Woolf, 1981).
Many explanations for this phenomenon have been suggested which have
centered largely on changes within the central nervous system. These potential
mechanisms include enhanced production/release of glutamate and
neuropeptides in the spinal cord (Belanger et al., 2002; Ibuki et al., 2003; Mao et
al., 2002), protein kinase C -induced signaling (Lim et al., 2005), spinal
Ca2+/calmodulin-dependent protein kinase II alpha activity (Chen et al., 2010),
enhanced descending facilitation of nociceptive pathways from the rostral
ventromedial medulla (Vanderah et al., 2001) and activation of non-classical
opioid receptors (Lewis et al., 2010). Alternative peripheral mechanisms also
include sensitization of peripheral nociceptors (Aley and Levine, 1997; Liang et
al., 2008).
The mechanisms responsible for morphine induced SDF1/CXCR4
signaling in primary sensory neurons of the DRG are largely unknown. Thus, the
effects we have observed might be downstream of morphine’s interactions with
µ-opioid receptors or possibly through interactions with TLR4 as has been
recently suggested (Hutchinson et al., 2010). A number studies have been
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conducted demonstrating the ability of chemokines and opioid agonists
administration to induce heterologous desensitization to their respective systems
(Szabo et al., 2002; Chen et al., 2007b). These studies have clearly shown that
there is a relationship between the chemokine and opioid signaling pathways
during acute administration. However, our results expand on these studies by
suggesting that following the chronic administration of morphine produces an
alteration in sensory neuron SDF1/CXCR4 signaling that lasts for at least 5 days
after the last opioid injection.
With respect to morphine induced changes in CXCR4 activation, there
appear to be two important changes in the status of SDF1/CXCR4 signaling
within the DRG. First, it appears that greater CXCR4 signaling occurs following
the dosing regimen. This is indicated by the fact that during OIH there is an
AMD3100 reversible decline in CXCR4-ir in the DRG, presumably resulting from
SDF1 activation of CXCR4 receptors followed by their internalization and
recycling mechanisms, as previously observed in the dentate gyrus
(Bhattacharyya et al., 2008; Kolodziej et al., 2008). Secondly, the increased
SDF1/CXCR4 activation could result from enhanced tonic release of neuronal
SDF1 whose expression was upregulated under these conditions, or some
postsynaptic effect of morphine which produces enhanced CXCR4
desensitization in response to tonically released SDF1. In particular, the Ca2+
imaging experiments and the immunohistochemistry studies following AMD3100
administration clearly demonstrate that morphine treatment results in
considerable degree of upregulated expression of CXCR4 by DRG nociceptors.
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Our results highlight the rapid timecourse of CXCR4 downregulation and
recycling that occurs in the DRG and other cell types. Numerous studies have
demonstrated that the time course and extent of CXCR4 recycling in different cell
types is subject to a very large number of factors that can interact with the
receptor and regulate the different stages of endocytosis, and recycling or
degradation (Tarasova et al., 1998; Zhang et al., 2004b). Thus it is becoming
clear that regulating the levels of CXCR4 cell surface expression is one important
mechanism of adjusting the signaling possibilities through this pathway. As
activation of chemokine receptors expressed by DRG neurons produces
excitation (White et al., 2007), it is likely the activation of these receptors by
SDF1 contributes to the ectopic excitability of these neurons and produces
AMD3100 reversible tactile hypernociception. The transient effect of AMD3100
may be explained by the short half life of 0.9 hours following a single
administration (Hendrix et al., 2000). To this end, our observations support the
growing body of literature that chemokines can act as neurotransmitters under
some circumstances (White et al., 2007).
In the case of SDF1, its release mechanism may be unusual as it does not
seem to require a depolarization induced increase in Ca2+, in contrast to the
depolarization dependent release of MCP1. The different release mechanisms
may be due to the observation that the two chemokines appear to be stored in
separate subcellular compartments. Thus, it is possible that the SDF1 storage
vesicles may be released by lower levels of Ca2+ or by low Ca2+ in cooperation
with some other signaling mechanism. We demonstrated that morphine will
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increase the expression of SDF1 within DRG neurons. According to our data
increased concentrations of SDF1 within DRG neurons should result in increased
tonic release of the chemokine. The fact that appreciable levels of SDF1 may be
tonically released both in the DRG (data herein) and the dentate gyrus suggest
that SDF1 may generally be secreted in this way when utilized in the nervous
system (Bhattacharyya et al., 2008; Kolodziej et al., 2008). Until recently, CXCR4
was known to be the only receptor for SDF1. This idea was challenged when the
chemokine receptor, CXCR7, was shown to bind SDF1 (Balabanian et al., 2005).
Initially described as a scavenger receptor, more recent interactions describe
CXCR7 as possibly moderating the response of CXCR4 to SDF1 by internalizing
the ligand (Zabel et al., 2009). Whether SDF1/CXCR7 activation serves to
modulate OIH is unknown. However, we have observed that CXCR7 is
expressed in the DRG of adult mice (unpublished observations) and so this
remains a possibility.
In conclusion, ongoing SDF1/CXCR4 signaling within sensory neurons
provides a mechanistic basis for understanding OIH modifications within the
nervous system. Beyond its signaling relevance in the sensory neuron, the
relationship between neuronal expression of SDF1/CXCR4 and tactile
hypernociception in the rodent may imply that chemokine-sensitized sensory
neurons may serve as an excitatory signal central to OIH. Thus, OIH represents
another example of chronic pain behavior where chemokine signaling in DRG
neurons has been observed to be upregulated (White et al., 2009), further
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highlighting the potential role of chemokine signaling in the generation of chronic
pain.

CHAPTER THREE
THE ROLE OF OPIOID AND NON-OPIOID RECEPTOR SIGNALING IN
SDF1/CXCR4 INDUCED CHANGES IN THE DORSAL ROOT GANGLION
Overview
Opioid analgesics such as morphine represent one of the most effective
treatment options for moderate to severe pain. Clinical usage of opioid
analgesics while effective can also be accompanied by a number of side effects
such as respiratory depression, urinary retention, or dependence. Individuals
taking opioids such as, morphine can also develop increased pain sensitivity
referred to as opioid induced hypernociception (OIH). The mechanism behind
the development of OIH remains largely unknown. However, recent work in our
lab has implicated the upregulation of SDF1/CXCR4 signaling in OIH. The
purpose of the current study was to identify the receptor activation responsible
for the upregulation of chemokines in the DRG of animals exhibiting OIH. In
order to dissect the receptor activation events responsible we used
pharmacological tools with distinct receptor affinity patterns. In order to test the
role of non-opioid signaling we used the morphine metabolite, morphine 3-ß-Dglucuronide (M3G), and morphine co-administered with the non-selective opioid
antagonist naltrexone. The selective mu opioid receptor (MOR) agonist, D-Ala2,
N-MePhe4, Gly-ol-enkephalin (DAMGO), was employed to demonstrate the role
62

63

of MOR in changes in SDF1/CXCR4. We demonstrate that OIH is induced
through opioid and non-opioid signaling events as repeated administration of
DAMGO, M3G, and morphine co-administered with naloxone all induced
nociceptive behavior. However, only repeated DAMGO administration is able to
induce changes in SDF1/CXCR4 signaling in the rodent DRG. Changes in
SDF1/CXCR4 signaling within the DRG are indicated by a decrease in CXCR4immunoreactivity that is reversed by the CXCR4 antagonist, AMD3100.
Additionally, DAMGO-induced nociceptive behavior is partially reversed with the
administration of AMD3100. The data presented implicate MOR activation as
responsible for changes in SDF1/CXCR4 signaling previously witnessed with
morphine. Furthermore, the data demonstrate that the mechanism responsible
for inducing OIH involves both opioid and non-opioid receptor signaling events.
Therefore, future studies examining OIH should consider a multiple receptor
approach is needed in order to prevent the development of OIH, which would
lead to a better treatment options for pain management.
Background
Opioid analgesics typically have their greatest affinity for the mu opioid
receptor (MOR). Signaling through the MOR is also attributed to the analgesic
mechanism of action. The opioid analgesic, morphine, shares this affinity profile
having a greater affinity for MOR (14 nM) less affinity for the kappa opioid
receptor (538 nM) and lowest affinity for the delta opioid receptor (>1000 nM)
(Raynor et al., 1994). Morphine like any drug has affinity for multiple receptors
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and with an increased dose the probability of binding additional receptors
increases. Therefore, any effects adverse or therapeutic could be occurring
through opioid or non opioid receptor binding.
The receptor signaling events responsible for morphine-induced
hypernociception is still unclear. However, recent studies have shown that
morphine-induced hypernociception occurs in triple opioid knockout mice
demonstrating this behavioral state can induced through a non-opioid receptor
(Juni et al., 2007). The mechanism behind morphine’s non-opioid receptor
signaling ability is undetermined. However, one possible candidate is morphine
3-ß-D-glucuronide (M3G), the major metabolite of morphine, which has limited
affinity for all of the opioid receptors (Pasternak et al., 1987;Skarke et al., 2005)
and lacks analgesic ability (Pasternak et al., 1987; Ekblom et al., 1993). In fact,
M3G has been shown to be neuroexcitatory and capable of inducing nociceptive
behavior (Bartlett et al., 1994; Yaksh et al., 1986; Woolf and Fitzgerald, 1981;
Lewis et al., 2010). Therefore, M3G could be responsible for the non-opioid
signaling taking place with morphine but the receptor that is responsible for
binding M3G is unknown. Watkins and colleagues have suggested that M3G is
signaling through toll-like receptor 4 (TLR4) and that signaling through TLR4
leads to M3G-induced hypernociception (Lewis et al., 2010; Hutchinson et al.,
2009; Hutchinson et al., 2010. Further studies addressing this possibility are
needed.
Our previous studies with morphine demonstrated that morphine treatment
induced a persistent hypernociceptive state which can be transiently reversed by
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the CXCR4 antagonist, AMD3100 (Wilson et al., 2011). An interaction between
opioids and chemokines has previously been demonstrated by opioid agonists
such as, morphine and DAMGO, increasing CXCR4 and CCR5 on monocytes
and lymphoctyes (Steele et al., 2003). Additionally, a number of studies from the
Rogers and Adler group have demonstrated chemokine injections into the
periaqueductal grey (PAG) leads to a decrease in the anti-nociceptive effects of
opioids (Szabo et al., 2002; Chen et al., 2007a; b). Therefore, opioid receptor
signaling could be involved in morphine-induced changes in SDF1/CXCR4 and
hypernociceptive behavior.
The goal of our current study was to determine the receptor activation
responsible for inducing changes in SDF1/CXCR4 signaling we previously
witnessed following repeated morphine administration. Various pharmacological
tools were utilized to dissect the opioid and non-opioid receptor signaling
components. To test the role of opioid receptor signaling the selective MOR
agonist, DAMGO, was used. Examination of non-opioid receptor signaling, M3G
and morphine co-administered with the non-selective opioid antagonist,
naltrexone, were assessed in their ability to induce hypernociceptive behavior
and the changes in SDF1/CXCR4 signaling in the rodent DRG.
Methods
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard
rodent chow and water available ad libitum. Experiments were performed during
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the light cycle. These experiments were approved by the Institutional Animal
Care and Use Committee of Indiana University/Purdue University in Indianapolis.
All procedures were conducted in accordance with the Guide for Care and Use of
Laboratory Animals published by the National Institutes of Health and the ethical
guidelines of the International Association for the Study of Pain. All animals were
randomly assigned to either treatment or control groups.
Drugs and method of administration. All drugs were freshly prepared in saline
on the day of the experiment. Intraperitoneal (i.p.) injections were administered to
animals following light anesthesia. For all dosing paradigms, animals received 5
once daily injections of the following drugs: DAMGO, M3G, and morphine and
naltrexone. For D-Ala2, N-MePhe4, Gly-ol-enkephalin (DAMGO) experiments,
DAMGO was administered at a dose of 10 mg/kg and purchased from SigmaAldrich (St. Louis, MO). Morphine 3-ß-D-glucuronide (M3G) was administered in
doses of 1, 5, and 10 mg/kg, supplied by NIDA Drug Supply Program. For
morphine and naltrexone experiments, naltrexone (10 mg/kg) was administered
30 minutes prior to morphine (10 mg/kg) injection. Four hours following the first
naltrexone injection an additional naltrexone (10mg/kg) was administered.
Morphine sulfate and naltrexone were purchased from NIDA Drug Supply
Program and Sigma-Aldrich (St. Louis, MO), respectively. After tactile
hypernociception was established, animals were given an i.p. injection of
AMD3100 (10 mg/kg) five days after the last day of the dosing paradigm (PID5).
AMD3100 dose was determined from previous experiments in our lab
(unpublished observations, (Wilson et al., 2011).
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Tactile Behavioral assessment von Frey filaments were used to test
mechanical sensitivity before, during and after cessation of DAMGO, M3G, and
morphine + naltrexone administration. Prior to initial von Frey tactile testing, all
rodents were habituated to testing chambers for at least two days. Animals were
tested for baseline responses (BL) at least two times before undergoing the
injection paradigm (5 daily doses of M3G, DAMGO, or morphine + naltrexone).
Mechanical testing with von Frey filaments during dosing paradigm was limited to
injection day 3 (ID3) (data not shown). Behavioral assessment on ID3 occurred
18-20 hours after the ID2 drug administration and before ID3 drug treatment.
Additional behavioral assessment following drug or vehicle administration
occurred on post-injection day (PID) 5, 7, and 14. All behavioral testing was
performed by laboratory assistants who were blinded to the experimental
conditions and unfamiliar with the experimental aims.
The incidence of foot withdrawal in response to mechanical indentation of
the plantar surface of each hindpaw was measured with a von Frey filament
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots
are representative of the distal nerve distributions of saphenous, tibial and sural
nerves (medial to lateral) in the glabrous hindpaw. During each test, the rodent
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm
openings. The cage is elevated so that stimulation can be applied to each hind
foot from beneath the rodent. The filaments were applied in order of ascending
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force. Each filament was applied alternately to each foot and to each locus. The
duration of each stimulus was approximately 1 s and the inter-stimulus interval
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a
percentage of the 6 applications of each stimulus and the percentage of
withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et
al., 2003). The von Frey withdrawal threshold was defined as the force that
evoked a minimum detectable withdrawal observed on 50% of the tests given at
the same force level. For cases in which none of the specific filaments used
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to
define the threshold.
Tissue processing and immunocytochemistry for neural tissue. Lumbar (L3L6) DRG tissue was collected from DAMGO, M3G, morphine co-administered
with naltrexone, and naïve rodents after animals were sacrificed and
transcardially-perfused with saline followed by fixative. Fixed tissue was then
embedded for sectioning and processed using immunocytochemical
methodologies commonly used in this lab (Bhangoo et al., 2007a, Wilson et al.,
2011). Tissue sections from L4 and L5 were used in immunocytochemical
experiments. Tissue sections were blocked with natural horse serum blocking
buffer (SuperBlock® Blocking Buffer in PBS (Thermo Scientific, Rockford, IL,
Natural Horse Serum (3% v/v), Triton X (0.4% v/v)). Primary antisera used was
the anti-CXCR4 rat monoclonal antibody, 2B11 (1:20,000 dilution; BD
Biosciences, San Jose, CA) which binds to both human and mouse CXCR4
(Forster et al., 1998; Schabath et al., 1999). CXCR4 anti-body was dissolved in
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blocking buffer and incubated overnight. After primary incubation, slides were
incubated in secondary antibodies (1:1,000 dilution; anti-rat made in donkey
conjugated to CY3, Jackson ImmunoResearch, West Grove, PA).
Images were taken with an intensified CCD camera (Photometrics
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) using Nikon
Elements Software (Nikon Instruments Inc., Melville, NY). Tissue sections were
illuminated with a Lamda DG-4 175 W xenon lamp with an exposure time of 300
msec.
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6
DRGs were acutely dissociated using methods described by Ma and LaMotte
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naïve and
M3G treated animals four to six days following the last day of the dosing
paradigm. The DRGs were treated with collagenase A and collagenase D in
HBSS for 20 minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN),
followed by treatment with papain (30 units/ml, Worthington Biochemical,
Lakewood, NJ) in HBSS containing .5 mM EDTA and cysteine at 35°C. The cells
were then dissociated via mechanical trituration in culture media containing 1
mg/ml bovine serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis
MO). The culture media was DMEM, Ham's F12 mixture, supplemented with 10%
fetal bovine serum, penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2
supplement (Life Technologies). The cells were then plated on coverslips coated
with poly-L lysine and laminin (1 mg/ml) and incubated for 2-3 hours before more
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culture media was added to the wells. The cells were then allowed to sit
undisturbed for 12–15 hours to adhere at 37°C (with 5% CO2).
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was
placed onto the inverted microscope. Intracellular calcium was measured by
digital video microfluorometry with an intensified CCD camera (Photometrics
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) and Nikon
Elements Software (Nikon Instruments Inc., Melville, NY). Cells were illuminated
with a Lamda DG-4 175 W xenon lamp, and the excitation wavelengths of the
fura-2 (340/380 nm) were selected by a filter changer. Sterile solution was
applied to cells prior to chemokine application, any cells that responded to buffer
alone were not used in chemokine responsive counts. Chemokines were applied
directly into the coverslip bathing solution. If no response was seen within 1
minute, the chemokine was washed out. For all experiments, MCP1, SDF1,
regulated upon activation, normal T cell expressed and secreted
(RANTES/CCL5), and interferon-gamma-induced protein (IP10/CXCL10) were
added to the cells in random order, after which capsaicin (3nM), high K+ (50µM)
and ATP (3nM) were added. The chemokines used were purchased from R & D
Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the protein by the LAL
method), and all were used at a concentration of 100 nM to ensure maximal
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activation (Bhangoo et al 2007a; Bhangoo et al 2007b). Chemokines were
reconstituted in sterile 0.1%BSA/PBS, and aliquots were stored at -20°C.
Calcium imaging traces were analyzed by two independent analyzers and only
responses that were in agreement between two individuals were used in the
counts.
Statistics. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical
significance of differences in the mean threshold forces for foot withdrawal to
punctate indentation as a function of time and between experimental groups by
means of one-way analyses of variance (One-way ANOVA) followed by post hoc
pairwise comparisons (Tukey method). Statistical significance was set at
p < 0.05. GraphPad Software (LaJolla, CA) was used to determine the statistical
significance of differences in calcium response among naïve and treatment
groups using Chi-square test with Yates correction with p<0.05 set as statistical
significance.
Results
Repeated morphine 3-β-D-glucuronide (M3G) treatment leads to tactile
hypernociception which is not reversed CXCR4 antagonist, AMD3100
administration
Repeated M3G administration (5 mg/kg, once a day for 5 days) was tested
for its ability to induce tactile hypernociceptive as measured by von Frey
filaments. In our experiments tactile behavior was assessed prior to M3G
administration (BL) and five days post M3G dosing paradigm (PID5). The mean
paw withdrawal threshold (PWT) was significantly decreased at PID5 when

72

compared to BL (72±1.4 mN to 31±3.0 mN; n=6) (Fig. 12). A significant
decrease in PWT was also witnessed with 1 and 10 mg/kg, however, no dose
dependence was witnessed (Fig. 13).

Figure 12. Repeated morphine 3-β-D-glucuronide (M3G) treatment (5 mg/kg
for 5 days) results in the development of tactile hypernociception as measured
by von Frey filaments. ADM3100 (10 mg/kg) administration on PID5 does not
result in any change in the PWT. BL, Baseline, PID, post injection day, AMD,
AMD3100 (One-way ANOVA; ns, no significant difference between PID5 and
PID5+AMD3100) (n = 6).

The ability of the CXCR4 antagonist, AMD3100, to reverse M3G-induced
nociceptive behavior was assessed and no significant increase in PWT was
observed (Fig. 10). Suggesting that repeated M3G administration does not lead
to changes in SDF1/CXCR4 signaling.
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Figure 13. Repeated M3G treatment (1 and 10 mg/kg, i.p. for 5 days) results
in the development of tactile hypernociception as measured by von Frey
filaments. Repeated M3G administration at 1 mg/kg (A) and 10 mg/kg (B)
resulted in a decrease in paw withdrawal threshold at PID5 compared to BL.
ADM3100 (10 mg/kg, i.p.) administration on PID5 induces a statistical
decrease in PWT. BL, Baseline, PID, post injection day, AMD, AMD3100 (Oneway ANOVA; * p<0.01 significant difference between PID5 and
PID5+AMD3100) (n=6).
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CXCR4-immunoreactivity (ir) in rat DRG is unchanged following repeated
M3G treatment
CXCR4-ir in the rat DRG is largely limited to the nonmyelinating satellite
glial cells (SGCs) and a few neurons (Fig. 14A) in agreement with our previous
findings (Wilson et al., 2011). Our previous studies demonstrated following
repeated morphine administration (10 mg/kg, once a day injections for 5 days) a
decrease in the CXCR4-ir at PID5. However, repeated intraperitoneal M3G
injections (5 mg/kg) does not induce any change in CXCR4-ir in the rat DRG
(Fig. 14B). The lack of changes in CXCR4-ir supports the inability of the CXCR4
antagonist, AMD3100, to reverse M3G-induced hypernociception.

Figure 14. Repeated M3G injections does not change CXCR4-immunoreactivity
(-IR) in satellite glial cells of rat lumbar DRG sections compared to naïve.
Animals received repeated M3G injections (5mg/kg once daily for 5 days) and
tissue was collected at 5 days after the last M3G injection (PID5). CXCR4-IR
(red) is largely restricted to satellite glial cells is unchanged from naïve rodent
DRG (A) and M3G PID5 (B) (n = 4 for each group).
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Repeated morphine 3-β-D-glucuronide (M3G) does not increase functional
CXCR4 receptors on DRG neurons.
To further investigate the expression of functional CXCR4 receptor, we
utilized Fura-2 Ca2+ imaging studies in acutely dissociated lumbar DRGs derived
from animals subjected to repeated M3G conditions and naive controls from
previous studies. The time points used corresponded to time points used for
immunohistochemical and behavioral assessment (Figs. 12 and 14). The
acutely dissociated DRG preparations were categorized into three neuronal and
non-neuronal cell types: non-capsaicin sensitive neurons (high K and ATP
responsive), capsaicin sensitive neurons (capsaicin, high K, and ATP
responsive), and glia (ATP responsive only). These cell response criteria were
chosen strictly as an indicator of the types of cells that may be affected by the
repeated M3G treatment paradigm. The tested chemokines were selected so as
to activate a wide spectrum of chemokine receptors known to be expressed by
neurons and non-neuronal cells (CXCR4-SDF1/CXCL12, CXCR3-IP10/CXCL10,
CCR2-MCP1/CCL2, CCR5-RANTES/CCL5). The chemokine concentration used
for these experiments were based on their maximally effective concentrations
used in our previous observations on acutely dissociated DRGs (Bhangoo et al.,
2007a; Bhangoo et al., 2007b).
Naïve acutely dissociated DRGs produced [Ca2+]i changes in a small
percentage of neuronal and non-neuronal populations following application of all
chemokines (Table 3), as shown in our previous studies (Wilson et al., 2011).
Repeated M3G treatment induced a significant increase in the chemokine
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(MCP1, IP-10, and RANTES) responsiveness of non-capsaicin sensitive and
capsaicin sensitive neurons (Table 3). Interestingly, no significant increase in
SDF1 responsiveness occurred in any cell type following repeated M3G
treatment (Table 3). Therefore, it appears there is a lack of increased functional
CXCR4 receptors on DRG neurons following repeated M3G treatment in
agreement with the lack of changes in CXCR4-ir and inability of CXCR4
antagonist, AMD3100 to reverse M3G-induced tactile behavior.
Naïve

Percent Positive Responding Cells

SDF1
Non-capsaicin sensitive neuron
(n=85)
7% (6/85)
Capsaicin sensitive neuron
(n=72)
7% (5/72)

IP-10

MCP1

RANTES

4% (3/85)

4% (3/85)

14% (12/85)

0% (0/72)

6% (4/72)

4% (3/72)

Glia (n=44)

2% (1/44)

9% (4/44)

21% (9/44)

SDF1
Non-capsaicin sensitive neuron
(n=74)
18% (13/74)
Capsaicin sensitive neuron
(n=117)
11% (13/117)

IP-10

MCP1

RANTES

55%**(41/74)

28%**(21/74)

31%* (23/74)

27%**(31/117)

21%**(24/117)

26%**(30/117)

Glia (n=25)

0% (0/25)

4% (1/25)

8% (2/25)

21% (9/44)

M3G Treated
PID4-6

16% (4/25)

Table 3. Repeated M3G treatment does not induce any significant increase in the
percentage of nociceptive neurons that respond to SDF1 administration as indicated
by a change in intracellular calcium. Daily M3G injections (5 mg/kg for 5 days) were
administered to animals. Lumbar DRG were acutely dissociated from these animals
4-6 days following the last M3G injection. Following repeated M3G administration
there was a significant increase in calcium responsiveness with MCP1, IP-10, and
Rantes application in capsaicin sensitive and non-capsaicin sensitive neurons. No
significant increase was seen following SDF1 application in all cell types following
M3G administration (** p<0.001, * p<0.05, Chi-square with Yates correction).
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Repeated morphine and naltrexone treatment induces nociceptive behavior
that is not reversed by CXCR4 antagonist, AMD3100, administration
In order to ensure that M3G-induced signaling did not differ from nonopioid receptor signaling induced by morphine administration we used the nonselective opioid antagonist, naltrexone (10 mg/kg) co-administered with repeated
morphine (10 mg/kg) treatment. Naltrexone was selected over naloxone
because of its longer half-life (Verebey et al., 1976). Additionally, naltrexone was
administered prior to morphine (10 mg/kg) injections in order to antagonize any
opioid receptor activation with morphine administration and was administered
four hours later to maintain naltrexone serum levels (Kim et al., 1988). The
naltrexone dose of 10 mg/kg was used because of its ability to have full
occupancy of MOR (Brown and Panksepp, 2009). The dosing paradigm of
repeated morphine and naltrexone induced a reduction in PWT when compared
to BL (72.2±1.3 mN to 32.8±2.2 mN; n=8) (Fig. 15).
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Figure 15. Repeated morphine and naltrexone treatment induces tactile
hypernociception and which is not reversed with administration of the
CXCR4 antagonist, AMD3100. Morphine (10 mg/kg) and naltrexone (10
mg/kg) 5 day dosing paradigm induced a decrease in PWT at PID5
compared to BL. AMD3100 (10 mg/kg) does not induce a significant
change in PWT. BL, Baseline, PID, post injection day, AMD, AMD3100
(One-way ANOVA; ns, no significant difference between PID5 and
PID5+AMD3100). (n = 8).

The role of SDF1/CXCR4 signaling in this hypernociceptive behavior state
was tested using the CXCR4 antagonist, AMD3100. AMD3100 was unable to
reverse the morphine and naltrexone induced tactile behavioral state (Fig. 13).
Suggesting that SDF1/CXCR4 signaling is not involved in the hypernociceptive
behavior induced by morphine and naltrexone injections.
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CXCR4-ir is unchanged following repeated morphine and naltrexone
treatment
CXCR4-ir is localized in the SCCs in the naïve rat DRG (Fig. 16A) and is
unchanged following repeated morphine and naltrexone treatment (Fig. 16B).
The lack of changes in CXCR4-ir following repeated morphine and naltrexone
treatment supports the inability of AMD3100 to reverse tactile behavior.

Figure 16. Repeated morphine and naltrexone dosing paradigm does not
change CXCR4-immunoreactivity. Rodents were administered the morphine (10
mg/kg) and naltrexone (10 mg/kg) 5 day dosing paradigm and lumbar DRG were
collected 5 days following the last day of injections (PID5). CXCR4-ir (red) is
unchanged between naïve (A) and morphine and naltrexone (B) administration
lumbar DRG tissue sections. (n = 4 for each group).

Repeated DAMGO injections induce hypernociceptive behavior that is
partially reversed by administration of the CXCR4 antagonist, AMD3100
In order to determine the role of MOR activation in changes in
SDF1/CXCR4 signaling witnessed following repeated morphine treatment we
employed the selective MOR agonist, DAMGO. DAMGO has similar half-life
pharmokinetics to morphine, thus the same dosing paradigm was used (once a
day injections for 5 days) (Szeto et al., 2001). DAMGO is unable to cross the
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blood-brain-barrier and therefore is rarely administered systemically, however,
DAMGO (10 mg/kg, ip) injections have been shown to be anti-nociceptive to
guarding behavior and was employed in our studies (Craft et al., 1995). DAMGO
injections (10 mg/kg, once a day for five days) induced a hypernociceptive state
through a reduction in PWT at PID5 (27.2±1.7 mN; n=6) when compared to BL
(76.5±1.3 mN) (Fig. 17).
To test the role of changes in SDF1/CXCR4 signaling in DAMGO-induced
hypernociception, AMD3100 was administered five days following the last
DAMGO injection (PID5) and was able to significantly increase the PWT when
compared to PID5 prior to AMD3100 administration (27.2±1.7 mN to 45.2±3.0
mN; n=6) (Fig. 17).
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Figure 17. DAMGO-induced tactile hypernociception is partially reversed
with CXCR4 antagonist, AMD3100. Repeated DAMGO (10 mg/kg once
daily for 5 days) treatment decreases PWT measured 5 days following the
last DAMGO injection (PID5) when compared to BL. AMD3100 (10
mg/kg) injection significantly increases PWT compared to PID5. BL,
Baseline, PID, post injection day, AMD, AMD3100 (One-way ANOVA;
p<0.01, *Significant difference between PID5 and PID5+AMD3100) (n =
6).

Decrease in CXCR4-ir following repeated DAMGO administration is
transiently reversed with administration of CXCR4 antagonist, AMD3100
CXCR4-ir in the naïve rat lumbar DRG is localized primarily to the satellite
glial cells (Fig. 18A) and decreases following repeated DAMGO administration
(Fig. 18B). Following intraperitoneal administration of the CXCR4 antagonist,
AMD3100 (10 mg/kg) and sacrificing animals one hour post AMD3100 injection,
CXCR4-ir returns to near naïve levels (Fig. 18C). CXCR4-ir positive neurons
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(white arrows) are also evident in DAMGO treated lumbar DRG tissue sections
following AMD3100 administration (Fig. 16C). These findings mimic the changes
in CXCR4-ir that we observed in our previous studies following repeated
morphine administration (Wilson et al., 2011). Additionally, the presence of
CXCR4-immunopositive neurons supports the ability of AMD3100 to partially
reverse DAMGO-induced tactile hypernociception.

Figure 18. Repeated DAMGO administration induces a reduction in CXCR4immunoreactivity that is reversed by the CXCR4 antagonist, AMD3100. Rodents
received repeated DAMGO (10 mg/kg) dosing paradigm (once daily i.p. injections
for 5 days) and lumbar DRG were collected 5 days following the last DAMGO
injection (PID5). CXCR4-ir (red) is decreased following DAMGO administration (B)
compared to naïve lumbar DRG sections (A). Treatment with AMD3100 (10 mg/kg,
i.p.) 5 days following the last DAMGO injection (PID5 +AMD) reverses the decrease
in CXCR4-ir (C). White arrows indicate the presence of CXCR4-immunopositive
neurons following AMD3100 treatment (n = 4 for each group).

Discussion
Our results demonstrate that repeated M3G, DAMGO, and morphine coadministered with naltrexone are all capable of inducing nociceptive tactile
behavior. However, only repeated DAMGO administration induces changes in
SDF1/CXCR4 signaling, similar to those reported in our previous findings with
repeated morphine treatment (Wilson et al., 2011). This change in SDF1/CXCR4
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signaling is evident by the decrease in CXCR4-ir following repeated DAMGO
administration that is reversible by the administration of AMD3100, CXCR4
antagonist. Additionally, AMD3100 is able to partially reverse DAMGO-induced
tactile nociceptive behavior.
The results of our current study suggest that morphine-induced
nociceptive behavior is induced by two mechanisms, opioid and non-opioid
receptor signaling. MOR signaling through repeated DAMGO administration is
capable of inducing a decrease in paw withdrawal threshold. Similarly,
compounds that prevent or have limited opioid receptor signaling capability, M3G
and morphine co-administered with naltrexone, are also capable of inducing
nociceptive behavior. To our knowledge, we are the first to demonstrate the
ability of systemic M3G administration to induce nociceptive behavior.
Interestingly, although DAMGO, M3G, and morphine + naltrexone all induced
nociceptive behavior the behavior is not as long lasting (data not shown) as
previously seen with repeated morphine administration which persisted for at
least 28 days (Wilson et al., 2011). Therefore, the mechanism needed to
maintain the nociceptive behavior over time must require the signaling events
from both opioid and non-opioid receptors that would be occurring from morphine
treatment.
Our findings indicate that the changes in SDF1/CXCR4 signaling are
induced by MOR activation through DAMGO administration. These findings are
in agreement with previous studies conducted in immune cells (Happel et al.,
2008). These studies demonstrated that increased CXCR4 expression on
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leukocytes is induced with DAMGO administration and is naloxone reversible
(Happel et al., 2008). Therefore, while nociceptive behavior is capable of being
produced though opioid and non-opioid receptor signaling, the SDF1/CXCR4
signaling component of this behavior is dependent on MOR activation.
Treatment with the CXCR4 antagonist, AMD3100, only partially reversed
the nociceptive behavior following repeated DAMGO administration. However,
following repeated morphine administration AMD3100 was capable of fully
reversing the nociceptive behavior (Wilson et al., 2011). One possible
explanation behind these results is that DAMGO is unable to cross the blood
brain barrier and therefore any signaling it induces would be occurring in the
peripheral nervous system. While CXCR4 expression is limited in the spinal
cord, central canal and neuroepithelium, (personal observation), there is a great
deal of opioid receptor expression in the spinal cord (Kuhar et al., 1973; Pert et
al., 1976; Lamotte et al., 1976; Atweh and Kuhar, 1977; Fields et al., 1980;
Ninkovic et al., 1982). Therefore, perhaps opioid signaling in the CNS is needed
to perpetuate the changes in SDF1/CXCR4 signaling previously seen with
morphine administration.
An alternative explanation is that other opioid receptor signaling, DOR and
KOR, is needed to potentiate changes in SDF1/CXCR4 signaling. As noted
previously morphine has affinity for all three opioid receptors and therefore could
be signaling through KOR or DOR in order to induce changes. DOR signaling
could be involved in our previous findings with morphine, Gendron and
colleagues demonstrated that similar repeated morphine treatment induces
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increased DOR expression on the DRG cell membrane (Gendron et al., 2006).
DOR in the naive rat DRG is located in vesicles at the cell membrane and
following repeated morphine administration DOR are inserted into the cell
membrane (Gendron et al., 2006). DOR would be available for signaling and
have potential in potentiating changes in SDF1/CXCR4 signaling. Although,
studies conducted with a selective delta agonist such as, [D-Pen2,5] Enkephalin ,
[D-Pen2,D-Pen5] Enkephalin (DPDPE), could give a false negative result because
although DORs are not responsible for the initial signaling events with morphine,
DOR signaling events could occur with later morphine administration or signaling
events following the cessation of morphine administration. Morphine signaling
through the KOR should also be explored. KOR’s role in the changes in
SDF1/CXCR4 signaling is questionable. The selective KOR agonist, U-50488,
inhibits LPS and HIV-tat-induced increases in cytokine levels in a number of cell
types (Zhang and Rogers, 2000; Belkowski et al., 1995; Alicea et al., 1996;
Neudeck et al., 2003; Sheng et al., 2003). However, one study conducted by the
Rogers lab demonstrated that KOR activation is capable of increasing the
expression of CCR2 mRNA in thymocytes treated with LPS (Zhang and Rogers,
2000). Most studies point to an opposing effect between MOR and KOR in
cytokine expression and it would be interesting to see if this holds true in the
DRG. Furthermore, most of these studies were conducted in activated cells; the
ability of KOR agonist to induce changes in cells at a resting state should also be
explored.
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In conclusion, opioid and non-opioid receptor activation is responsible for
the induction of OIH. However, changes in SDF1/CXCR4 signaling found in our
previous studies with repeated morphine treatment (Wilson et al., 2011) are
dependent on mu opioid receptor activation. These findings are interesting
because the analgesic ability of opioids is also thought to result from mu opioid
receptor activation. Thus, new analgesic treatment options should take into
account both the beneficial and detrimental effects of opioid receptor activation
and attempt to develop treatments to address these issues.

CHAPTER FOUR
DISCUSSION

Chronic pain affects many individuals decreasing their quality of life. The
treatment options for controlling these individuals pain is limited and often times
ineffective. The mechanism of action behind most current therapies is unknown.
Much of this stems from a lack of understanding of the diverse causes of chronic
pain and all possible targets for drug treatments. A better mechanistic
understanding of current treatment options, such as opioid analgesics, would
allow for the development of new, more effective pain therapeutics and was
therefore the goal of this project. By providing a better understanding of opioid
agonist effects and receptor targets will allow for the development of more
effective opioid analgesics or alternative therapeutics.
Overview of Results
The purpose of this project was to examine the role of SDF1/CXCR4
signaling in opioid induced hypernociception and to identify receptor signaling
events responsible for these changes. The first part of the project was to first
establish a morphine dosing paradigm that would induce long lasting changes in
nociceptive behavior. The repeated morphine paradigm (once daily 10 mg/kg i.p.
injections for 5 days) induced tactile nociceptive behavior that persisted for at
87
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least 28 days following the cessation of morphine administration. No change in
thermal behavior was witnessed, which is in contrast to other dosing protocols of
opioids of twice daily injections or intrathecal administration (Mao et al., 1994;
Raghavendra et al., 2004). The systemic morphine dosing paradigm was
selected because it better mimics the route of administration in the clinical
setting.
Following the establishment of long lasting nociceptive behavior we found
this morphine dosing paradigm induces changes in SDF1/CXCR4 signaling in the
DRG. The decrease and return of CXCR4-ir in rodent DRG tissue sections
witnessed coincides with the development and recovery of OIH. Furthermore,
administration of the CXCR4 antagonist, AMD3100, following the cessation of
morphine administration transiently reversed the established tactile nociceptive
behavior. Indicating the central role that SDF1/CXCR4 signaling is playing in
OIH. Administration of AMD3100 revealed the tonic activation process taking
place between SDF1 and CXCR4 in the rodent DRG through the ability of
AMD3100 to reverse the decrease in CXCR4-immunoreactivity. Release studies
in F11 cells provided evidence of SDF1’s constitutive release characteristics
further validating the tonic activation between SDF1 and CXCR4 in the rodent
DRG following morphine administration.
The second part of this project focused on investigating the receptor
signaling events responsible for the observed morphine-induced tactile behavior
and changes in SDF1/CXCR4 signaling. Tactile nociception was found to be
[88]
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induced by both non-opioid receptor signaling compounds, M3G and morphine
co-administered with the non selective opioid antagonist, naltrexone, and the
selective MOR agonist, DAMGO. These results suggest that OIH witnessed with
repeated morphine administration is induced by opioid and non-opioid receptor
signaling events. However, changes in SDF1/CXCR4 signaling in the rodent
DRG were found to be dependent on MOR activation, as shown by repeated
DAMGO administration.

Figure 19. Proposed Mechanism. Morphine action through the MOR
induces changes in SDF1/CXCR4 signaling. These changes in
SDF1/CXCR4 signaling were found to be contributing to the hyperexcitable
state of the nociceptive pathway as the CXCR4 antagonist, AMD3100, is
capable of transiently reversing nociceptive behavior.
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Another notable finding from this project was revealed in the calcium
imaging studies. All chemokines examined (SDF1, RANTES, MCP, IP-10) had a
significant increase in responsive neurons following morphine administration.
Following M3G administration all chemokines except for SDF1 had a significant
increase in the percentage of responsive neurons. These results indicate that
signaling from other chemokine and receptor pairings are upregulated in both
morphine and M3G tactile nociceptive behavior states. Further investigation into
the role of other chemokines in each of those tactile behavior states is warranted.
A preliminary study evaluating MCP1/CCR2’s role in OIH presented in Appendix
B. CCR2 antagonism was incapable of reversing morphine induced tactile
behavior (Fig. 18). These results were surprising following calcium imaging
studies revealing an increase in MCP1 responsive neurons, indicative of
increased functional CCR2. The calcium imaging and behavioral studies were
conducted at the same time point following repeated morphine treatment.
However, an increase in CCR2 positive neurons is not indicative of increased
signaling. The absence of a CCR2 ligand in the DRG would prevent increased
CCR2 signaling, thereby preventing the ability of CCR2 antagonism to be
successful at reversing any established nociceptive behavior. Therefore, these
results indicate the importance of multiple techniques in demonstrating changes
in chemokine signaling. Changes in receptor or ligand expression are not
sufficient in demonstrating a central component of any physiological state.
Additionally, changes in MCP1/CCR2 or the other chemokines could require a
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longer time to develop. Further studies investigating the time course of the
development of chemokine changes and the role of the other chemokines in OIH
is warranted.
Possible non-opioid receptor targets
Our results using non-opioid signaling compounds to induce tactile
nociceptive behavior were not surprising. Previous studies in triple opioid knockout mice revealed morphine’s retained ability to induce nociceptive behavior (Juni
et al., 2007). Additionally, intrathecal administration of M3G induces nociceptive
behavior (Lewis et al., 2010). However, studies investigating the receptor or
receptors responsible for these non-opioid signaling compounds effect are
largely limited. Watkins and colleagues propose that TLR4 is the receptor
responsible for these changes (Lewis et al., 2010; Hutchinson et al., 2009;
Hutchinson et al., 2010. My data presented in Appendix A demonstrate a
significant increase in the number of TLR4 responsive neurons following
morphine and M3G administration (Table 3). Additionally, immunocytochemistry
studies reveal the presence of TLR4-ir positive neurons in the lumbar DRGs of
naïve, morphine, and M3G treated animals (Fig 17A). Repeated morphine (10
mg/kg) and M3G (10 mg/kg) both induced a significant increase in TLR4-positive
neurons (Fig 17B). The presence of TLR4-positive neurons show the possibility
of TLR4 signaling to be occurring in the rodent DRG. However, the binding
ability of morphine and M3G to TLR4 and the ligand responsible for increased
TLR4 signaling within the DRG needs to be further examined.
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An alternative explanation for the increased LPS responsiveness following
morphine and M3G could be linked to increased neuronal CXCR4 expression.
CXCR4 has been proposed to be part of the LPS “sensing apparatus”
(Triantafilou et al., 2008). These studies conducted in CXCR4 transfected HEK
cells demonstrate that both SDF1 and LPS are capable of inducing changes in
IL-6 levels, p-MAPK, and inducing chemotaxis (Triantafilou et al., 2008). Indeed
LPS competitively inhibit the binding of SDF1 in CXCR4 transfected HEK cells.
Therefore, the increases in LPS calcium responsiveness could be occurring from
the increased CXCR4 neuronal expression. However, the presence of increased
LPS responsiveness following M3G administration, conditions where SDF1
responsive cells are not significantly increased suggests that a separate LPS
signaling receptor is required. The specific receptor responsible for non-opioid
signaling has yet to be determined and future studies investigating this topic
would serve to provide better more selective opioid analgesics.
CXCR7
With the discovery of SDF1’s capability of binding to not only CXCR4 but
also CXCR7 raises the question of CXCR7’s role in SDF1 signaling (Balabanian
et al., 2005). CXCR7 was initially described as a scavenger receptor
(Boldajipour et al., 2008; Dambly-Chaudiere et al., 2007); more recent
interactions describe CXCR7 as possibly moderating the response of CXCR4 to
SDF1 by internalizing the ligand (Zabel et al., 2009). Although CXCR7 does not
elicit activation of G-protein signaling pathways, it does activate MAP kinases
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through β-arrestin (Rajagopal et al., 2010) and is therefore capable of altering the
excitation state of cells. Additionally, like SDF1, AMD3100 was previously known
to selectively block CXCR4 signaling. Recent studies have demonstrated that
SDF1 and AMD3100 both stimulate arrestin recruitment to CXCR7, and
AMD3100 may act as an allosteric agonist of CXCR7 (Kalatskaya et al., 2009). If
so, changes in CXCR7 neuronal expression in the DRG following M3G
administration (1 and 10 mg/kg, i.p.) could explain the significant decrease in
paw withdrawal threshold following AMD3100 administration in these animals
(Fig. 11). However, the presence of CXCR7 in the rodent DRG is unknown and
future studies would need to be conducted to investigate this possible signaling
event. These results would challenge the effectiveness of AMD3100 in states
where both CXCR4 and CXCR7 are both present.
Given the possibility that CXCR7 signaling via β-arrestin may contribute to
SDF1-mediated cellular functions following repeated morphine treatment, it is
important to know the neuronal distribution of CXCR7 in the rodent. The lack of
reliable CXCR7 antibodies thus far has prevented the ability of anatomical
localization of this receptor in the rat DRG. However, CXCR7-GFP mice
developed in Dr. Richard Miller’s lab increase the expression CXCR7 in both
sensory neurons and SGCs following LPS treatment (unpublished observations).
Merely the observation of neuronal CXCR7, regardless of the conditions,
provides us with a basis to speculate about possible SDF-1 influences on
CXCR7 in the DRG, including neuronal excitability. One possibility that has been
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described in T cell lymphocytes is that CXCR7 forms heterodimers with CXCR4
which may alter CXCR4 Gαi-protein activation and subsequent calcium fluxes
(Levoye et al., 2009). Additionally, CXCR7 could be working in our model of
repeated morphine treatment to further regulate the levels of SDF1 in the DRG.
Clearly, the role of CXCR7 in neurobiology still needs to be determined and its
role in nociceptive states is an area requiring further investigation.
SDF1/CXCR4 Changes in Satellite Glial Cells
Changes in SDF1/CXCR4 signaling in sensory neurons directly affect the
nociceptive behavior witnessed in OIH. However, the reduction in CXCR4immunoreactivity in the satellite glial cells (SGC) following repeated morphine
and DAMGO administration demonstrate increased SDF1/CXCR4 signaling in
SGCs as well. While SDF1/CXCR4 signaling in SGCs would be indirect the
signaling event could still be contributing to OIH. A potential mechanism of
SDF1/CXCR4 signaling in SGCs could be occurring through the release of proinflammatory mediators into the milieu of the DRG thereby, indirectly affecting the
excitatory state of sensory neurons. Recent evidence has emerged that
implicates SDF1 induction of the pro-inflammatory cytokine, IL-6 (Tang et al.,
2008) and may also control expression of other chemokines such as neuronal
fractalkine (Cook et al., 2010). SDF1’s ability to induce IL-1β would further
contribute through the paracrine interactions within the rat DRG. IL-1β can be
released from satellite glial cells whereupon it acts on nearby small-diameter
sensory neurons bearing interleukin type I receptor (IL-1RI) (Takeda et al., 2008).
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In turn, IL-1β signaling significantly increases the spontaneous neuronal activity
in Aδ mechanosensitive neurons and may be important in hypernociception
(Takeda et al., 2008). Furthermore, it is commonplace that cytokines induce
chemokine promoter activation and increase secretion of chemokines during
inflammation, which could be responsible for the maintenance of the observed
OIH behavior.
The satellite glial cells in the rodent DRG could have an alternative role.
In the naïve rodent DRG the majority of CXCR4 expression is located on SGCs.
However, the role that CXCR4 expression on SGCs is playing in OIH was not
addressed in these studies. One possibility is that CXCR4 on SGCs is acting as
a “sink” for released SDF1, serving to buffer any SDF1 that is released within the
DRG or SDF1 from the systemic circulation. In support of this theory, calcium
imaging studies conducted on acutely dissociated DRGs, only 20 percent of glial
cells have a calcium response to SDF1 in both naïve and morphine treated
conditions (Wilson et al., 2011). This suggests SDF1/CXCR4 signaling in SCCs
occurs through a different mechanism. SDF1 is unable to bind the non-signaling
chemokine receptors, D6 and DARC, and was shown to be alternatively
internalized by CXCR4 to maintain the homeostatic levels of SDF1 (Dar et al.
2005). This theory would coincide with other studies that have shown the ability
of SGCs to take up molecules from the milieu of the DRG (Kumamoto et al.,
1986; Schlaepfer, 1969). This mechanism supports the need for CXCR4 on
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SGCs to act as a buffering system for circulating SDF, preventing any
unnecessary CXCR4 activation by circulating levels of SDF1.
Opioid-induced changes in PNS chemokine/ receptor expression
The mechanisms underlying the effects of chronic opioid treatment on
chemokine/receptor expression are not fully understood, but is based on
evidence that opioids stimulate the production and release of cytokines in many
cell types including leukocytes, keratinocytes, and glial cells (Volk et al., 2004;
Messmer et al., 2006; Wang et al., 2007; Liang et al., 2008; Johnston et al.,
2004; Tai et al., 2006). It is well known that cellular activation by these cytokines
initiate signaling cascades that eventually lead to the expression of
chemokines/receptor. For example, upregulation of CXCR4 following DAMGO
administration is thought to be dependent on the naloxone-reversible increases
in TGF-β production (Chao et al., 1992; Steele et al., 2003; Happel et al., 2008).
Chronic morphine treatment also increases the expression of the chemokine
receptors, CCR2 and CCR5, in human astrocytes and CCL2 in human neurons
via largely unknown mechanisms (Mahajan et al., 2005; Rock et al., 2006).
Taken together, this evidence suggests that chronic opioid treatment directly or
indirectly can lead to upregulation of chemokine signaling in leukocytes, neurons
and glial cells.
Despite evidence of direct or indirect, opioid-induced transcription factor
regulation in variety of cells types, little work has been conducted to investigate
transcriptional control of chemokine/receptor expression in either glial cells or
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neurons. The promoter regions of a number of chemokine/receptors were
analyzed by Hosung Jung in the Miller lab and candidate transcription factors
were identified which include NFAT, NF-KB, CREB, and C/EB. The Miller lab
further investigated the transcriptional control of chemokines in F11 cells and
acutely dissociated sensory neurons subjected to pathological circumstances of
chronic excitability (Jung and Miller, 2008). Jung and Miller (2008) demonstrated
that DRG-like F11 cells expression of the chemokine receptors, CCR2 and CCR5
is depended on nuclear factor of activated T cells (NFAT) activation, whereas
chemokine receptor, CXCR4, was not. With this outlined information known
about the transcriptional control of chemokines and their receptors which of these
transcription factors is induced by opioid treatment needs to be examined.
Opioid receptor control of transcription factors has been explored in a
number of different cell types. Neurons, macrophages, and immune cells treated
with MOR agonists induce the activation and increased DNA binding of the
transcription factors NF-KB, CREB, and AP-1 (Hou et al., 1996; Roy et al., 1998;
Bilecki et al., 2004; Happel et al., 2010). Furthermore, DAMGO treatment
increases CCL2 expression in polymorphonuclear cells which is dependent on
NF-KB activity (Happel et al., 2010). Selectively targeting the downstream
transcriptional regulation of chemokines and receptors following opioid
administration could serve to prevent some of the detrimental effects of opioid
analgesic and improve their therapeutic effects.
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Chemokines Role in Inflamed vs. Un-inflamed Tissue
Cells of the immune system utilize the chemoattractant gradient of
chemokines in order to localize to sites of injury. Stein and colleges were able to
demonstrate a secondary role in which the chemokine CXCL2/3 is able to
stimulate the release of opioids from opioid-containing immune cells such as
leukocytes (Rittner et al., 2006). This chemokine-induced release of endogenous
opioids is beneficial and analgesic when chemokines are injected into the
hindpaw in a model of inflammatory pain (Rittner et al., 2006). This is in direct
contrast to the nociceptive effects of chemokines injected into an un-inflamed
hind paw (Oh et al., 2001).

In the un-inflamed hindpaw the chemokines have

no opioid containing immune cells to act on and are in this instance detrimental
because chemokines are capable of activating sensory neurons (White et al.,
2005).
SDF1 was also tested in these studies and was unable to induce
the release of endogenous opioids from leukoctyes expressing CXCR4 (Rittner
et al., 2006). However, SDF1 application did not lead to as substantial of a
calcium response at the concentration used and the concentration of SDF1
needed to induce a significant chemotactic response was 100 fold greater than
that required for CXCL2/3 (Rittner et al., 2006). Additionally, while SDF1 was not
found to be analgesic in these studies SDF1 did not induce to a nociceptive
response (Rittner et al., 2006), which differs from the findings of SDF1 in an un-
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inflammed paw (Oh et al., 2001). Suggesting a greater concentration of SDF1
might be needed for the same response seen with CXCL2/3.
Findings from our lab and others demonstrate that opioid administration
from both in vitro and in vivo studies act to increase the expression of both
chemokines and their receptors on cells of the immune and nervous system
(Steele et al., 2003; Miyagi et al., 2000; Rock et al., 2006; Mahajan et al., 2005;
El-Hage et al., 2006; Wilson et al., 2011). It can be theorized that opioid-induced
increases in chemokine/receptors expression would beneficial in inflammatory
pain states of which opioids are often employed. In these conditions opioids
would act to increase the expression of chemokines/receptors and would thereby
increase the infiltration of immune cells and increase the release of endogenous
opioids at the site of injury. Opioid usage in non-inflammatory pain states would
increase the expression of chemokines/receptors however; the absence of
opioid-containing immune cells for the chemokines to act upon would be
disadvantageous. Without the presence of opioid containing immune cells, the
chemokines would act directly on the sensory neurons, inducing a hyperexcitable
state. This explanation could explain why OIH in the clinical setting is reported at
a site separate from the injury. At the injury site the opioid-induced increase in
chemokine/receptor expression would be analgesic inducing an increase in the
release of endogenous opioids. However, following the systemic administration
of opioids locations away from the site of injury would also have increased
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expression of chemokine/receptor, but the lack of infiltrated immune cells at
these sites would lead to a hypernociceptive state.
If this theory holds true future use of opioids in pain treatment should
consider the use of locally applied opioids. This approach would allow for the
beneficial effectiveness of opioids, acting directly on sensory neurons and
inducing increased expression of chemokines/receptors locally, thereby
increasing the release of endogenous opioids and recruitment of other immune
cells needed for healing. Furthermore, local opioid treatment would prevent the
increase in chemokine signaling at sites separate from the injury site and avoid
the hypernociceptive state that can be induced from systemic opioid
administration. The analgesic ability of locally applied morphine has been
demonstrated in clinical studies following knee surgery and chronically inflamed
tooth pain (Dionne et al., 2001; Likar et al., 1999; Stein et al., 1991). In two of
the studies locally applied morphine had a higher analgesic effect than systemic
morphine (Dionne et al., 2001; Stein et al., 1991). An additional benefit of local
application of opioids is the avoidance of a number of problematic side effects of
opioids such as, respiratory depression and urinary retention.

APPENDIX A:
TLR4 DISTRUBUTION IN DORSAL ROOT GANGLION AND LPS
RESPONSIVE CELL IN ACUTELY DISSOCIATED DORSAL ROOT
GANGLION
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Methods
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard
rodent chow and water available ad libitum. Experiments were performed during
the light cycle. These experiments were approved by the Institutional Animal
Care and Use Committee of Indiana University/Purdue University in Indianapolis.
All procedures were conducted in accordance with the Guide for Care and Use of
Laboratory Animals published by the National Institutes of Health and the ethical
guidelines of the International Association for the Study of Pain. All animals were
randomly assigned to either treatment or control groups.
Drugs and method of administration. All drugs were freshly prepared in saline
on the day of the experiment. Intraperitoneal (i.p.) injections were administered to
animals following light anesthesia. For all dosing paradigms, animals received 5
once daily injections of the following drugs: M3G (1, 5, and 10 mg/kg) and
morphine sulphate (10 mg/kg). Morphine 3-ß-D-glucuronide (M3G) and
morphine sulfate were supplied by NIDA Drug Supply Program.
Tissue processing and immunocytochemistry for neural tissue. Morphine,
M3G or naïve control treatments rats’ lumbar (L3-L6) DRG tissue was collected
after animals were sacrificed and transcardially-perfused with saline followed by
fixative. Fixed tissue was then embedded for sectioning and processed using
immunocytochemical methodologies commonly used in this lab (Bhangoo et al.,
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2007a). Tissue sections from L4 and L5 were used in immunocytochemical
experiments. Primary antisera used was the anti-TLR4 goat M16 extracellular
monoclonal antibody, (1:200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz,
CA). After primary incubation, slides were incubated in secondary antibodies
(anti-goat made in horse conjugated to CY3, Jackson ImmunoResearch,West
Grove, PA). Positive control immunocytochemistry staining was conducted in rat
spleen sections. Specific labeling of white pulp was observed.
Cell Counts. Images were taken with an intensified CCD camera (Photometrics
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) using Nikon
Elements Software (Nikon Instruments Inc., Melville, NY). Tissue sections were
illuminated with a Lamda DG-4 175 W xenon lamp. Within elements software
each images maximum threshold was set between 8000 and 8500. Total cell
counts for each section were taken using the grid function to aide in total cell
count. TLR4 positive cell counts were conducted using Image Pro Software
(Media Cybernetics, Bethesda, MD). The following parameters were used for
cell counts: Intensity range (40-255), smoothness (20), measurement window
size (10µM-∞). Images fluorescent artifacts such as axons and cell debris were
unselected so that these were not used in cell counts. TLR4 cell counts were
taken from each tissue section image and combined for each treatment group.
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6
DRGs were acutely dissociated using methods described by Ma and LaMotte
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naïve, M3G,
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and morphine-treated animals four to six days following the last day of the dosing
paradigm. The DRGs were treated with collagenase A and collagenase D in
HBSS for 20 minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN),
followed by treatment with papain (30 units/ml, Worthington Biochemical,
Lakewood, NJ) in HBSS containing .5 mM EDTA and cysteine at 35°C. The cells
were then dissociated via mechanical trituration in culture media containing 1
mg/ml bovine serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis
MO). The culture media was DMEM, Ham's F12 mixture, supplemented with 10%
fetal bovine serum, penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2
(Life Technologies). The cells were then plated on coverslips coated with poly-L
lysine and laminin (1 mg/ml) and incubated for 2-3 hours before more culture
media was added to the wells. The cells were then allowed to sit undisturbed for
12–15 hours to adhere at 37°C (with 5% CO2).
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was
placed onto the inverted microscope. Intracellular calcium was measured by
digital video microfluorometry with an intensified CCD camera (Photometrics
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) and Nikon
Elements Software (Nikon Instruments Inc., Melville, NY). Cells were illuminated
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with a Lamda DG-4 175 W xenon lamp, and the excitation wavelengths of the
fura-2 (340/380 nm) were selected by a filter changer. Sterile solution was
applied to cells prior to chemokine application, any cells that responded to buffer
alone were not used in chemokine responsive counts. Chemokines were applied
directly into the coverslip bathing solution. If no response was seen within 1
minute, the chemokine was washed out. For all experiments, MCP1, SDF1,
regulated upon activation, normal T cell expressed and secreted
(RANTES/CCL5), and interferon-gamma-induced protein (IP10/CXCL10) were
added to the cells in random order. Following chemokine application LPS
(1µg/mL) was applied to coverslip, after which capsaicin (3nM), high K+ (50µM)
and ATP (3nM) were added. The chemokines used were purchased from R & D
Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the protein by the LAL
method), and all were used at a concentration of 100 nM to ensure maximal
activation (Bhangoo et al 2007a; Bhangoo et al 2007b). Chemokines and LPS
were reconstituted in sterile 0.1%BSA/PBS, and aliquots were stored at -20°C.
Calcium imaging traces were analyzed by two independent analyzers and only
responses that were in agreement between two individuals were used in the
counts.
Statistics. GraphPad Software (LaJolla, CA) was used to determine the
statistical significance of differences in calcium response and TLR4-positive
neurons among naïve and treatment groups using Chi-square test with Yates
correction with p<0.05 set as statistical significance.
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Results
Repeated morphine and M3G administration induces a significant increase
in TLR4-positive neurons.
Animals were subjected to repeated administration of morphine (10 mg/kg, once
daily for 5 days) and M3G (1, 5, and 10 mg/kg, once daily for 5 days) and lumbar
DRG were collected from animals 5 days following the last injection. TLR4positive neurons (red) were present under all conditions (Fig. 20A). A significant
increase in TLR4-immunopositive neurons was present following repeated
morphine (10 mg/kg) and M3G (10 mg/kg) administration as compared to naïve
DRG tissue (Fig. 20B). Each treatment condition had similar numbers of total
numbers that were analyzed (Fig. 20C).
LPS responsive neurons are significantly increased following repeated
morphine and M3G administration.
Lipopolysaccharide (LPS) is a major part of the outer component of gram
negative bacteria that is crucial for the virulence of the bacteria (Cryz et al.,
1984). LPS-induced effects have been demonstrated to dependent on binding to
CD14 and TLR4 receptors (Pugin et al., 1993; Hoshino et al., 1999).
Furthermore, LPS induced calcium response can be blocked by both CD14 and
TLR4 antibodies (Song et al., 2001). Therefore, to investigate the presence of
functional TLR4 receptors within the rodent DRG we applied LPS to acutely
dissociated DRGs. The acutely dissociated DRG preparations were categorized
into three neuronal and non-neuronal cell types: non-capsaicin sensitive neurons
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(high K and ATP responsive), capsaicin sensitive neurons (capsaicin, high K, and
ATP responsive), and glia (ATP responsive only). These cell response criteria
were chosen strictly as an indicator of the types of cells that may be affected by
the repeated morphine and M3G treatment paradigm. Naïve acutely dissociated
DRGs produced LPS-induced [Ca2+]i changes in a small percentage of neuronal
and non-neuronal populations (Table 4). Repeated morphine (10 mg/kg) and
M3G (10 mg/kg) treatment induced a significant increase in LPS calcium
responsiveness of non-capsaicin sensitive and capsaicin sensitive neurons
(Table 4). While the calcium imaging data does not conclusively demonstrate
that increased TLR4 neuronal expression is causing the increased LPS
responsiveness, it does demonstrate increased LPS response which is known to
cause increase intracellular calcium levels through TLR4 (Song et al., 2001).
This along with the increased TLR-4 positive neurons suggests TLR4 could be
mediating this response (Fig. 20B). Further studies would need to be conducted
to validate TLR4 is responsible for this increased signaling.
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Figure 20. TLR4-ir positive neurons are significantly increased following
repeated morphine (10mg/kg) and M3G (10 mg/kg). Tissue sections taken from
naïve, morphine, and M3G treated animals were collected 5 days following the
last injection, representative images are presented for TLR4-ir positive neurons
(red) (A). Cell counts from tissue section images were conducted and there was
a significant increase in TLR4-positive neurons in morphine (10mg/kg) and M3G
(10 mg/kg) animals when compared to naïve (B). Total neuron cell counts were
similar among treatment groups (C). (* p value <0.01, Chi-square with Yates
Correction).
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Naïve

Non‐capsaicin sensitive neuron
Capsaicin Sensitive neuron
Glia

6% (5/85)
8% (6/72)
7% (3/44)

Morphine (10 mg/kg)
Treated
Percentage Positive Response
23% (26/112)**
36% (26/73)**
16% (8/49)

M3G (5 mg/kg) Treated

31% (23/74)**
25% (29/117)*
0% (0/25)

Table 4. Repeated morphine and M3G treatment significantly increase the percentage
of LPS responsive neurons as measured by a change in intracellular calcium. Daily
morphine and M3G administration (10 mg/kg for 5 days) were administered to animals.
Lumbar DRG were acutely dissociated at 4-6 days following the last injection of morphine
or M3G. (** p<0.001, * p<0.05, Chi-square with Yates correction).

APPENDIX B:
CCR2 RECEPTOR ANTAGONISM DOES NOT REVERSE MORPHINEINDUCED TACTILE HYPERNOCICEPTION
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Methods
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard
rodent chow and water available ad libitum. Experiments were performed during
the light cycle. These experiments were approved by the Institutional Animal
Care and Use Committee of Loyola University, Chicago. All procedures were
conducted in accordance with the Guide for Care and Use of Laboratory Animals
published by the National Institutes of Health and the ethical guidelines of the
International Association for the Study of Pain. All animals were randomly
assigned to either treatment or control groups.
Drugs and method of administration The drugs, morphine sulfate salt and the
CCR2 antagonist (R)-4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3hydroxy-1,5-dihydro-2H-pyrrol-2-one (CCR2 RA), were employed in this study.
Morphine sulfate salt and CCR2 RA were supplied by the NIDA Drug Supply
Program (Rockville, MD) and Eli Lilly (Indianapolis, IN), respectively. All drugs
were freshly prepared in saline on the day of the experiment. Morphine sulfateand vehicle-treated groups were given intraperitoneal (i.p.) injections once daily
for 5 days of 10 mg/kg or saline (vehicle). After tactile hypernociception was
established, animals were given an i.p. injection of CCR2 RA (10 mg/kg) 5 days
following the last morphine injection (PID5).
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Tactile Behavioral assessment von Frey filaments were used to test
mechanical sensitivity before, during and after cessation of morphine sulfate
administration. Prior to initial von Frey tactile testing, all rodents were habituated
to testing chambers for at least two days. Animals were tested for baseline
responses (BL) at least two times before undergoing the repeated morphine
sulfate treatment (10 mg/kg, i.p. daily). Mechanical testing with von Frey
filaments during the morphine sulfate dosing paradigm was limited to injection
day (ID) 3. Behavioral assessment on ID3 occurred 18-20 hours after the ID2
morphine administration and before ID3 morphine or vehicle treatment.
Additional behavioral assessment following drug or vehicle administration
occurred on post-injection day (PID) 3, 5, 7, and 14. All behavioral testing was
performed by laboratory assistants who were blinded to the experimental
conditions and unfamiliar with the experimental aims.
The incidence of foot withdrawal in response to mechanical indentation of
the plantar surface of each hindpaw was measured with a von Frey filament
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots
are representative of the distal nerve distributions of saphenous, tibial and sural
nerves (medial to lateral) in the glabrous hindpaw. During each test, the rodent
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm
openings. The cage is elevated so that stimulation can be applied to each hind
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foot from beneath the rodent. The filaments were applied in order of ascending
force. Each filament was applied alternately to each foot and to each locus. The
duration of each stimulus was approximately 1 s and the inter-stimulus interval
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a
percentage of the 6 applications of each stimulus and the percentage of
withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et
al., 2003). The von Frey withdrawal threshold was defined as the force that
evoked a minimum detectable withdrawal observed on 50% of the tests given at
the same force level. For cases in which none of the specific filaments used
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to
define the threshold.
Statistics. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical
significance of differences in the mean threshold forces for foot withdrawal to
punctate indentation as a function of time and between experimental groups by
means of one way analyses of variance (one-way ANOVA) followed by post hoc
pairwise comparisons (Tukey method).
Results
Morphine-induced tactile hypernociception is not reversed with CCR2
receptor antagonist.
Animals were administered morphine (10 mg/kg, one a day for five days) and
tactile behavior was assessed with von Frey filaments. Behavioral assessment
of tactile hypernociception was performed prior to the start of the injection
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paradigm (BL), during the 5 day dosing regimen (ID), and following the repeated
morphine treatment paradigm (PID) (Fig.21). The mean paw withdrawal
threshold (PWT) of the tested hind paws exhibited a significant decrease at ID4,
PID3, and PID5 as compared to BL (Fig. 21). Administration of the CCR2
receptor antagonist (10 mg/kg, i.p.) at PID5 did not induce a significant change in
PWT as compared to PID5 prior to injection (Fig. 21).

Figure 21. CCR2 receptor antagonism does not reverse morphine
induced tactile hypernociception. Repeated morphine treatment (10 mg/kg
for 5 days) results in the development of tactile hypernociception as
measured by von Frey filaments. Five days following the last morphine
injection (PID5) rats received an i.p. injection of CCR2 antagonist (10
mg/kg) and tactile behavior was measured by von Frey filaments 1 hour
post injection. BL, baseline, ID, injection day, PID, post injection day,
CCR2 RA, CCR2 receptor antagonist (One-way ANOVA; *p<0.05,
significant difference from baseline) (n=6)
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